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Parkinson’s disease is the second most common neurodegenerative disease. This disease 
is caused by the degeneration of dopaminergic neurons, leading to debilitating motor 
symptoms and early mortality. The protein α-synuclein (α-syn), encoded by SNCA, 
misfolds and forms inclusions in Parkinson’s disease brains. When α-syn is 
overexpressed in yeast, it causes cellular toxicity and an increased number of aggregates, 
recapitulating the toxic phenotypes observed in humans and animal models. Yeast models 
are a powerful tool to perform high-throughput overexpression screening to identify 
modifiers of α-syn toxicity. α-syn causes mitochondrial dysfunction by inhibiting 
complex I and inducing mitochondrial fragmentation. Prior screening of α-syn were 
limited to only the galactose condition, where mitochondrial function is dispensable. 
Previous screening was performed exclusively with the GAL1 promoter, restricting the 
genes to only those induced by galactose. We have validated an overexpression system 
using GAL3 alleles that can induce genes under mitochondrial-dependent glycerol-ethanol 
condition and other non-galactose conditions (calorie restriction, nitrogen starvation and 
raffinose). α-syn showed discrepancy in the correlation of toxicity and aggregation in 
non-galactose conditions. Compared to galactose, under glycerol-ethanol condition, α-syn
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exhibited higher toxicity, formed more aggregates, and decreased viability and 
respiratory competency despite having similar expression under the two conditions. We 
screened 14,827 human gene clones and identified 87 that can suppress α-syn toxicity in 
glycerol-ethanol. Genes involved in RNA polymerase II function, anterior-posterior axis 
and nucleoplasm were overrepresented. Among the suppressor hits, we identified four 
14-3-3 protein isotypes (b, g, q, and z). None of the four suppressors suppressed the 
toxicity under galactose. However, the 14-3-3 suppressors did not reduce aggregates 
under glycerol-ethanol. No increase in respiratory competency was observed; however, 
14-3-3b was seen to effectively reduce the number of cells that accumulate ROS. Overall, 
we have created an overexpression system that describes a new path for performing 
screening in non-galactose conditions. Our results based on novel phenotypes of α-syn 
show that screening in these conditions is indeed important. We have identified 
previously unknown suppressors of α-syn toxicity and ruled out underlying mechanisms 
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Parkinson’s disease and α-synuclein 
Parkinson’s disease is the second most common neurodegenerative disease 
worldwide.1 Parkinson’s disease is a motor disorder that presents with three cardinal 
symptoms: bradykinesia (slow movement), rigidity, and tremors. Nonmotor symptoms, 
including cognitive impairment, autonomic dysfunction, sleep disorders, and depression 
also affect the patient’s quality of life. Parkinson’s disease is an aging disease with the 
prevalence increasing from 0.3% in the general population, to greater than 4% among 
individuals over 85 years of age.2,3 The disease is difficult to treat because once the first 
symptoms appear, 60% of motor neurons have already degenerated. As such, the 
prevalence of Parkinson’s disease is expected to double by the year 2030,4 adding 
tremendously to the ever-increasing medical economic burden associated with the 
disease. Furthermore, the mortality rate is double that of the healthy general population,5 
with available treatment strategies neither modifying the progression of the disease nor 
delaying the onset of disability. Hence, there is an incredible impetus for further research 
in this field.6 
 Neurologically, Parkinson’s disease is characterized by the degeneration of 
pigmented dopaminergic neurons in the substantia nigra pars compacta of the midbrain 
and histologically, by the presence of Lewy bodies which are intracellular α-synuclein (α-
syn) aggregates.7 Although the specific underlying cause of Parkinson’s disease is 
unknown, a combination of genetic mutations and environmental factors appear to play a 
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role. Further, over 90% of the disease incidence is sporadic, meaning there is no family 
history of disease; while approximately 10% of the disease incidence is familial, meaning 
there is a family member who has the disease. There are six genes whose mutations have 
been linked to Parkinson’s disease,8 although mutations are responsible for less than 5% 
of the overall incidence. Mutations in SNCA and leucine-rich repeat kinase 2 (LRRK2) 
genes cause autosomal dominance, whereas those in ATP13A2, Parkin, phosphatase and 
tensin homolog-induced kinase 1 (PINK1), and DJ-1 cause autosomal recessive disease. 
Autosomal dominant disease is a pattern of inheritance in which an affected individual 
has one copy of a mutant gene and one normal gene on a pair of autosomal 
chromosomes. Autosomal recessive diseases are caused by two copies of the mutant gene 
on a pair of autosomal chromosomes. Individuals with autosomal dominant diseases have 
a 50% chance of passing the mutant gene on to each of their children. 
SNCA was the first gene identified whose mutations, duplications and triplications 
were found to cause Parkinson’s disease.9 SNCA mutations cause early onset (< 50 years 
of age) Parkinson’s disease and are associated with high mortality.10 Patients with 
triplication of the SNCA have much earlier disease onset and rapid progression compared 
with patients with duplication of SNCA.11 The widely studied missense mutations of 
SNCA include A30P, E46K, A53T, G51D, and H50Q.12 α-syn protein, encoded by SNCA, 
is a small 140-amino acid cytoplasmic protein that belongs to the synuclein family and is 
primarily expressed in the brain.13 Mutations, duplications and triplications of SNCA 
accelerate aggregation of the α-syn resulting in intracytoplasmic neuronal inclusions 
which constitute the Lewy bodies.14,15 Lewy bodies are present in 95% of Parkinson’s 
disease brains even in the absence of SNCA mutations.16 Although the precise mechanism 
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responsible for initiating the misfolding and aggregaiton of α-syn remains 
uncharacterized, environmental and stress factors such as higher pH and temperature, as 
well as oxidative stress appear to play a role. 
Misfolding and aggregates of α-synuclein cause Parkinson’s disease 
α-syn consists of three domains: an amphipathic N-terminal domain, a 
hydrophobic center, and a hydrophilic C-terminal domain. This composition results in an 
α-helical, random loop formation that facilitates the interactions of α-syn with 
phospholipid-containing membranes including those of the mitochondria, endoplasmic 
reticulum (ER)/Golgi and the nucleus.17,18 The ability to interact with organelle 
membranes makes α-syn a molecular chaperone, enabling docking of synaptic vesicles to 
the cell membrane and facilitating intracellular protein trafficking.17,19 Through these 
mechanisms, α-syn regulates cellular functions such as neuronal differentiation,20 
apoptotic inhibition,21 regulation of synaptic plasticity,22 and regulation of dopamine 
release.23 
Further, α-syn is an unfolded protein in its native form; however, mutations in 
SNCA together with environmental factors (e.g., oxidative stress, pesticide or metal 
exposure) cause misfolding of α-syn which then becomes tightly configured in long 
filamentous protofibrils and fibrils.24 The distinctive feature of the α-syn aggregation is 
the slow primary nucleation process that becomes accelerated when in contact with the 
lipid membranes.25 Nucleation involves the formation of a β-sheet core that folds into 
itself and aggregates with others to form protofilaments; from the protofilaments, mature 
fibrils are formed.26 Under normal conditions, a-syn exists as monomers, which form 
soluble oligomers on contact with cellular membranes and then assemble into insoluble 
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fibrils when triggered by several stressors (e.g. SNCA mutations, duplications, and 
triplications, oxidative stress, metal exposure, etc.,). The cells protective systems, 
including the lysosome autophagy system and ubiquitin proteasome system, prevent the 
toxic forms from spreading across the neurons resulting in Lewy body formation.27 α-syn, 
in its aggregate state, contains five β-sheet cores of amyloid fibrils, each comprised of 35 
– 96 amino acid residues (N-terminal amphipathic region). The point-mutations are 
primarily located within this core region.26 Missense SNCA mutations can increase the 
rates of fibril formation initiation and their proliferation, however, does not affect fibril 
elongation.28 
ER-associated misfolded protein degradation in yeast 
Under normal conditions, the misfolded proteins are processed by the ubiquitin 
proteasome system or the autophagy-lysosome pathway.29 The ER plays a major role in 
protein quality control. In the ER, once the protein undergoes post-translational 
modifications, it must become properly folded before transport to the Golgi apparatus. 
Consequently, if the protein becomes misfolded, it will not enter the Golgi but will 
instead be redirected to the ER-associated degradation (ERAD) pathway.30,31 There are 
four major proteins that make up the ERAD pathway namely, Yos9, Der1, Hrd3, and 
Usa1. These four proteins, along with the Hrd1/Der3 (E3 ubiquitin ligase) complex, 
recognize the substrate (misfolded protein) at the ER.32 Once recognized, it is 
ubiquitinated and Hrd1 mediates the retro-translocation to the Cdc48 complex.33,34 
Substrate delivery cofactors Rad23 and Dsk2 aid in further recognition of the substrate by 
the 26S proteasome where the deubiquitinating enzymes (Rpn11 and Ubp6) remove the 
polyubiquitin chain and are then degraded.35 Perturbations in the ER quality control lead 
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to the accumulation of misfolded proteins and cause ER stress. The unfolded protein 
response (UPR) pathway is the cell’s protective mechanism against ER stress. UPR is 
associated with an increase in ER chaperones, glycosylases and ERAD proteins 
(increasing the protein folding capacity) and degradation of messenger ribonucleic acid 
(mRNA) (decreasing the protein influx).36 If a large amount of misfolded proteins 
accumulate, uncontrolled UPR results in increased production of reactive oxygen species 
(ROS) from the ER and mitochondria, which in turn induces caspase-mediated 
apoptosis.37 
ER stress has been reported in Parkinson’s disease patient brains38 as well as in 
genetic models of α-syn overexpression.39,40 In fact, levodopa, a Parkinson’s disease 
therapeutic drug, attenuated ER stress in neuronal cell cultures.41 α-syn is not a resident 
ER protein; however, it has been shown to consistently interact with the ER, thereby 
inhibiting the ER-Golgi transport system in yeast.39,42 Although, the overexpression of α-
syn alone did not induce UPR and ER stress, the association between α-syn and the ER 
membrane did.40 
Additionally, deletion of YCA1, a yeast orthologue of mammalian caspase, leads 
to accumulation of damaged cells due to an absence of apoptosis.43 Disruption of UPR or 
the deletion of YCA1 did not prevent α-syn mediated apoptosis in yeast; however, yeast 
lacking mitochondria (ρ° cells) prevented apoptosis.44 Taken together, these studies 
suggest that α-syn may interact with biological membranes and/or synaptic vesicles, 
permitting it to transform into an aggregated form which then causes ER stress and 
disrupts protein trafficking. The resulting accumulation of misfolded proteins activates 
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UPR, increases ROS production and causes caspase-mediated apoptosis that is primarily 
dependent on mitochondrial function. 
α-synuclein and mitochondrial dysfunction 
Mitochondria and a-syn have been independently shown to cause both familial and 
idiopathic Parkinson’s disease.45–47 Several studies have shown that a-syn increases 
fragmentation of the mitochondria, independent of the mitochondrial fission protein 
Dynamin-related protein 1 (Drp1).48 Furthermore, a-syn can localize to the nucleus under 
oxidative stress, where it binds to the peroxisome proliferator-activated receptor γ 
coactivator 1 α (PGC1α) promoter, thereby decreasing PGC1a-regulated genes and 
indirectly affecting mitochondrial function.49 PGC1α is a member of a family of 
transcription coactivators that plays a central role in mitochondrial biogenesis. In human 
dopaminergic neuron cultures, cell lines and transgenic mouse models, a-syn has been 
shown to reduce complex I activity, and increase mitophagy.50–53 Both wild-type (WT) 
and mutant a-syn increase ROS production.54–56 Additionally, fluorescence resonance 
energy transfer analysis showed that a-syn preferentially interacts with mitochondria 
over the ER and other synaptic vesicles.57 Overall, a-syn reduces mitochondrial function 
via several mechanisms including, reducing complex I activity, increasing mitochondrial 
fragmentation and mitophagy, and accelerating ROS production. 
The association of Parkinson’s disease and mitochondria was first reported in the 
1980s, when the use of the mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) as an illegal drug was found to lead to the development of 
Parkinson’s disease-like symptoms.58 Further, systemic infusion of rotenone (electron 
transport chain inhibitor) in animal models59 and mutations in DJ-1, a mitochondrial ROS 
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scavenger, have been shown to cause Parkinson’s disease;60 while mutations in PINK161 
and Parkin,62 associated with Parkinson’s disease, cause reduced complex I activity and 
adenosine triphosphate (ATP) synthesis. Lastly, a conditional knockout of mitochondrial 
transcription factor A in dopaminergic neurons causes respiratory chain deficiency and a 
Parkinson’s disease-like phenotype including motor dysfunction.63 It is, therefore, 
apparent that mitochondria play a central role in the development and progression of 
Parkinson’s disease. 
Yeast screening models identified functions of α-synuclein 
Researchers have used the yeast Saccharomyces cerevisiae to understand the 
mechanisms of α-syn induced cellular toxicity.64 Specifically, when the human SNCA is 
overexpressed in yeast under a GAL1 promoter, the toxicity has been found to increase 
with increasing copy number.65 Concordantly, the increasing copy number is associated 
with increase in the number of intracellular inclusions.66 Moreover, in yeast, mutations or 
overexpression of SNCA triggers aggregate formation, inhibit vesicular trafficking, cause 
mitochondrial dysfunction, and reduce proteasome degradation, recapitulating the cellular 
phenotypes of Parkinson’s disease present in humans.67 In addition, overexpression 
screening in yeast has led to the improved understanding of the cellular functions of α-
syn that were previously unknown.68 Results of α-syn overexpression screening have 
been validated in both in vitro and in vivo neuronal models.69 
Two major yeast genetic overexpression screening studies39,42 were performed, 
which identified 77 previously unknown genetic modifiers of α-syn toxicity. In these 
screens, the transmembrane ATPase Yor291w (yeast homolog of ATP13A2) was 
identified as a suppressor of α-syn toxicity; while mutations in ATP13A2 induced 
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juvenile onset Parkinson’s disease. Interestingly, yeast were employed to identify the 
connections between these two unrelated genes (ATP13A2 and SNCA).42 Indeed, 
Caenorhabditis elegans and rat midbrain cultures were used to verify that ATP13A2 
antagonized α-syn-mediated dopaminergic neuronal degeneration.42 Further, we now 
know that vesicular transport plays a key role in Parkinson’s disease pathology because 
of yeast modifier screening. In fact, YPT1, a guanine triphosphatase (GTPase) that 
enhances ER-Golgi trafficking, suppressed a-syn toxicity while GYP8, which converts 
YPT1 to its inactive state, enhanced a-syn toxicity.39 Yeast screening assays have not 
only been used to identify critical cellular perturbations in Parkinson’s disease, but also to 
assess the efficacy of therapeutic agents (N-aryl benzimidazole) for the suppression of a-
syn mediated toxicity.69 
Drawback of prior yeast screening models 
All screening studies mentioned above were performed exclusively under 
galactose growth conditions. Since, SNCA and the yeast genes that were screened were 
under the GAL1 promoter, galactose is essential to induce overexpression of these genes. 
Galactose is a fermentable carbon source and undergoes glycolysis. Hence, under 
galactose conditions, yeast do not require mitochondrial oxidative phosphorylation for 
metabolism.70 Given that a-syn affects mitochondria in multiple ways, screening for 
modifiers in only galactose conditions would likely cause modifiers of a-syn toxicity 
related to mitochondria and the respiratory function of the cell to be overlooked. 
Luckily, the ability of yeast to grow on non-fermentable carbon sources (where 
mitochondrial function is essential for survival) will allow us to perform screening under 
a mitochondrial-dependent growth condition. We sought to develop an overexpression 
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system with the capacity to induce gene expression under non-galactose conditions, 
specifically those containing glycerol. Glycerol metabolizes to one molecule of pyruvate 
and two nicotinamide adenine dinucleotide hydrogen (NADH). Only one of the NADH 
molecules is used to ferment pyruvate to ethanol (Figure 1); while the other NADH 
causes a redox imbalance, forcing the NADH to enter the mitochondria for oxidative 
phosphorylation,71 making glycerol a mitochondrial-dependent growth condition. We 
hypothesized that performing the screening under glycerol-rich conditions will permit the 
identification of novel modifiers of a-syn toxicity. This hypothesis was supported by a 
yeast screening study examining differences between fermentable and non-fermentable 
conditions, which revealed 794 genes to be differentially expressed.72 When cells were 
transferred from glucose to glycerol conditions, the transcriptome levels of as many as 
1284 RNAs increased. Further, under glycerol conditions, genes involved in 
mitochondrial metabolism including those associated with electron transport chain, 
oxidative phosphorylation, and tricyclic acid cycle, had increased expression. Thus, 
metabolism, gene and protein expression all vary widely between fermentable and non-
fermentable carbon source. Since a-syn affects mitochondria, inducing overexpression of 
a-syn in glycerol will allow for identification of previously overlooked and interesting 
results. 
Constitutive GAL3 alleles induce GAL1 promoter in glycerol condition 
The GAL1 promoter has an upstream activating sequence that is bound by Gal4p, 
the transcriptional activator, which in turn is repressed by Gal80p, the transcriptional 
repressor. Under galactose, Gal3p, the protein encoded by GAL3, undergoes 





Figure 1. Glycerol metabolism in yeast 
Metabolism of glycerol results in one molecule of pyruvate and two molecules of NADH. 
Only one of the two released NADH molecules can be used to ferment pyruvate to 
ethanol. The additional NADH causes redox imbalance, forcing the NADH to become 




to one that is ‘closed active’. The closed conformation allows Gal3p to bind and remove 
Gal80p from Gal4p, resulting in expression of the target gene.73,74 GAL3 alleles had 
previously been shown to constitutively induce the GAL1 promoter in glycerol condition 
in the absence of galactose by inducing the ‘closed’ conformation of Gal3p.75 We wanted 
to test if these alleles can be utilized to induce the GAL1 promoter not just in galactose 
but also in other non-galactose growth conditions. GAL1 promoter was preserved because 
it provides a simple switch in gene regulation as growth on galactose medium induces 
expression, whereas growth on glucose represses expression.76,77 Glucose repression 
would help eliminate the problem of cellular toxicity in expressing a-syn. Thus, we chose 
three GAL3 alleles (GAL3F237Y, GAL3A368V and GAL3S509P)75 from the previous 









II. MATERIALS AND METHODS 
 
Yeast strains, media, and plasmids 
Yeast strains, plasmids, and polymerase chain reaction (PCR) primers used in this study 
are listed in Tables 1–3, respectively. Yeast cells were grown using standard methods. 
Briefly, for integrated strains, including NoTox, IntTox and HiTox a-syn, fused in 
sarcoma (FUS), TAR DNA-binding protein 43 (TDP-43), and mutant huntingtin 
(HTT103Q), yeast cells were precultured in yeast peptone dextrose (YPD) medium. 
Yeast containing free plasmids were precultured in selective medium containing 2% 
glucose. Precultures with optical densities between 8–14 at 600 nm (OD600) were washed 
with double distilled water and transferred to selective medium containing specific 
carbon sources. Mating of yeast strains was performed either in YPD liquid medium or 
YPD agar plates. The carbon sources used in this study include 2% glucose, 2% 
raffinose, 2% galactose, 0.5% glucose, 0.1% glucose, and 3% glycerol with 1% ethanol. 
The nitrogen starvation conditions lacked ammonium sulfate, whereas the other 
conditions contained ammonium sulfate (5 g/L). Yeast were incubated at 30 °C either in a 
shaker or a stationary incubator for 3 h to 5 d, depending on the experimental 
specifications. IntTox a-syn yeast strain was a gift from the Susan Lindquist Lab.  
Gateway cloning 
The LR reaction is a technique used to transfer entry clone plasmids to yeast 
expression vectors, enabling expression of the target gene in yeast cells.78 This reaction 
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included a 10 μL mixture containing 100 ng of entry clone plasmid deoxy-ribonucleic 
acid (DNA), 150 ng of destination vector plasmid, 3 µL LR clonase, and Tris EDTA (TE) 
buffer. The contents were mixed thoroughly and incubated at 25 °C overnight. Next, 
DH5a competent bacterial cells were transformed with 5 µL of the LR reaction mixture 
using the bacterial transformation technique. The expression clone was then extracted 
from the bacteria using a plasmid miniprep kit according to manufacturer’s instructions 
(Zymo Research, California, USA) and confirmed with restriction enzyme digestion 
and/or Sanger sequencing. 
Site-directed mutagenesis 
Primers for GAL3 alleles were designed online using the QuikChange Primer 
Design Program available at www.agilent.com/genomics/qcpd (Table 2 and 3). PCR for 
mutagenesis was set up by creating a 50 µL mixture containing 5 µL of 10× Pfu reaction 
buffer, 50 ng template DNA, 125 ng each of forward and reverse primers, 1 µL 
deoxyribonucleotide triphosphate (dNTP), 1 µL Pfu, and double distilled water. Next, 
parental DNA from the reaction mixture was digested with DpnI, and 2 µL of the 
digested content was transformed into DH5a bacterial cells. A minimum of two, and a 
maximum of four bacterial colonies were picked for each allele, and the mutations were 
confirmed by Sanger sequencing. 
One-step yeast transformation 
Yeast were grown overnight and washed twice with distilled water, and 1 mL of 
culture was mixed with transformation buffer (80 µL of 50% polyethylene glycol (PEG) 
3350, 10 µL of 1 M dithiothreitol, and 10 µL of 1 M lithium acetate).79 No DNA was 
added to the negative control; to the remaining samples, 100–200 ng plasmid DNA was 
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added to the mixture and incubated in a 42 °C water bath for 1 h. The samples were then 
plated on selective agar plates containing glucose or YPD (with or without drugs based 
on the plasmid) and incubated at 30 °C for 3 days. Single colonies were isolated, and 
glycerol stocks were obtained and used for further experiments. 
Yeast mating 
Single colonies of yeast strains of opposite mating types with different 
auxotrophic markers were streaked on YPD agar plates in a cross pattern and incubated at 
30 °C for 16 h. The center of the cross was then streaked to double dropout agar plates. 
Plates were incubated at 30 °C for 3 d or until individual colonies were visible. For 
library screening, two yeast strains of opposite mating types were freshly grown 
separately in selective medium in 96-well plates. Using pins, the two strains were 
transferred and mixed in 96-well plates containing 160 µL of YPD. The cells were 
allowed to grow overnight to form diploids, which were then transferred using pins into 
triple dropout liquid medium containing 2% glucose for selection. 
β-Galactosidase assay 
A microplate stopped assay protocol was used to perform β-galactosidase assays 
(ThermoFisher Scientific, Massachusetts, USA). Briefly, a yeast strain (W303 MATa) 
was integrated with the pRS303-LacZ plasmid (Table 2).80 This strain was then mated 
with GAL3 allele strains (W303 MATa), resulting in diploid yeast. Single colonies were 
grown on double selective 2% glucose medium overnight. Once an OD600 of 0.1 was 
observed, cultures were shifted to many growth conditions: 0.1%, 0.5%, and 2% glucose; 
2% galactose; 2% raffinose with and without ammonium sulfate; 2% glucose without 
ammonium sulfate; and 3% glycerol with 1% ethanol. After the cells reached log phase 
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with an OD600 reading between 0.6 and 1.8, 70 µL of the working solution (35 µL β-
galactosidase buffer and 35 µL Y-Per reagent) was added to 70 µL yeast culture in each 
well, and a timer was started. Duplicates of each culture were used to assess 
reproducibility. When a yellow color became visible in the wells, 56 µL of the stop 
solution was added to each well, the plates were vortexed for 30 s at 1,000 rpm, the timer 
was stopped, and the total reaction time was recorded. The plates were then centrifuged at 
1,850 rpm for 5 min, and 160 µL of the supernatant was transferred to flat-bottomed 96-
well plates. The absorbance at 420 nm (A420) of each well was measured using a 
microplate reader (Fisher Scientific, Ontario, Canada) with the well containing water as 
the blank. The formula used to calculate β-galactosidase activity was: 




where, t is the time (in min), V is the volume of cells in mL (0.070 mL), A420 is the 
absorbance at 420 nm, and OD600 is the optical density at 600 nm. 
Serial dilution growth assays 
Yeast were grown overnight in YPD or selective medium containing 2% glucose. 
Yeast cultures were normalized to an OD600 of 1.0. A 10-fold serial dilution was 
performed 4 times, and the diluted samples were spotted in a horizontal pattern on 
synthetic agar plates with the following carbon sources: 0.1%, 0.5%, and 2% glucose; 2% 
galactose with or without ammonium sulfate; 2% raffinose with or without ammonium 
sulfate; 2% glucose without ammonium sulfate; and 3% glycerol with 1% ethanol. Plates 




Proteins were extracted from yeast cells using a post-alkaline extraction method.81 
The extracts were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and transferred to polyvinylidene difluoride membranes, which were then 
rinsed with water and blocked with 5% non-fat dry milk in tris-buffered saline with tween 
20 (TBST) for 1 h. Incubation with primary antibodies was performed overnight at 4°C. 
The membrane was washed five times for 5 min each in TBST and then incubated with 
secondary antibodies for 1 h at room temperature. The membrane was washed again five 
times for 5 min each in TBST and developed with nitro blue tetrazolium (NBT)/5-bromo-
4-chloro-3-indolyl-phosphate (BCIP) solution (ThermoFisher Scientific, Massachusetts, 
USA). The primary antibodies used were anti-green fluorescent protein (GFP; ab6556, 
Abcam, Cambridge, UK) and anti-phosphoglycerate kinase 1 (PGK1; PA5-28612, 
Invitrogen, California, USA) at a dilution of 1:10,000. PGK1 is a key enzyme in 
glycolysis and gluconeogenesis and localizes to the plasma membrane, mitochondria and 
cytoplasm. PGK1 is an essential yeast gene and null mutants are unable to grow in 
glucose, galactose or glycerol carbon sources; and thus, it was chosen as the loading 
control. The secondary antibodies used were alkaline phosphatase-conjugated anti-rabbit 
and anti-mouse antibodies at a dilution of 1:10,000. The experiment was repeated thrice 
unless otherwise specified. Image quantification was performed using ImageJ software 
with PGK1 as the reference bands. 
Fluorescence microscopy 
Yeast strains were grown overnight in selective medium containing 2% glucose. 
Cultures were centrifuged at 3,900 rpm for 5 min, washed twice with sterile water, and 
then resuspended in medium containing either 2% galactose or 3% glycerol with 1% 
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ethanol. The cultures were diluted to a starting OD600 of 1.0 and incubated at 30 °C to 
induce protein expression for 3–18 h. Cultures were harvested, centrifuged, and 
resuspended in sterile water. Three µL of the resuspension were then placed on a 
microscope slide with a cover slip. An Olympus IX83 inverted fluorescent microscope 
and Olympus DP74 digital camera (Olympus, Japan) were used to capture images at 40× 
magnification using fluorescein isothiocyanate, yellow fluorescent protein (YFP), cyan 
fluorescent protein (CFP), and Texas Red (Tx Red) filter cubes (chroma 39002, 39003, 
49001, and 39010, respectively). Brightfield images were obtained before switching to 
other channels. 
Quantification of a-synuclein aggregates 
The YFP microscopic pictures obtained were used for counting. The total number 
of cells and number of cells with aggregates were counted using Image J software and 
verified manually. A minimum of 200 cells per biological repeat were counted. The 
percentage of cells containing aggregates was calculated as the ratio of the number of 
cells with aggregates to the total number of cells. 
Examination of mitochondria 
The MitoLoc plasmid (pMitoLoc) was purchased from Addgene. pMitoLoc 
contained two fluorescently tagged proteins that both localized to the mitochondria - GFP 
fused to the fungal mitochondrial localization signal of the F0-ATPase subunit 9 
(preSu9), a mitochondrial membrane potential independent signal and mCherry protein 
fused to the N-terminal localization sequence of cytochrome C oxidase 4 (preCOX4), 
imported into mitochondria proportional to the membrane potential. Expression of 
plasmids was achieved by transforming the plasmid into yeast strains and plating on agar 
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plates containing the antibiotic nourseothricin.82 Since SNCA, tagged with a YFP, 
overlapped with the GFP signal of pMitoLoc, we re-engineered the plasmid to replace 
preSu9-GFP with preSu9-teal fluorescent protein (preSu9-TFP). First, we amplified the 
TFP sequence by PCR with an overhang sequence of the GFP upstream region in the 
pMitoLoc. The downstream region of GFP was also amplified by PCR with part of the 
overhang sequence of mTFP. The two amplified products were further merged by PCR. 
The pMitoLoc and the final PCR product were digested and ligated, resulting in 
replacement of preSu9-GFP with preSu9-TFP. This enabled us to visualize SNCA 
simultaneously with the mitochondrial structure and membrane potential - SNCA in 
yellow, all mitochondria in teal, and healthy mitochondria in red. pMitoLoc was 
transformed into the two strains - the vector (pRS303-GAL) and α-syn. Mating was then 
performed with the strain containing GAL3A368V. Diploid yeast strains were induced in 
galactose and glycerol-ethanol for 6 and 18 h, at which point microscope images were 
captured. For Aim 3, the suppressor and vector plasmids were transformed into the α-syn 
containing pMitoLoc. Merging of mitochondrial images were performed using ImageJ 
software. 
Quantification of viable and respiratory-competent cells 
Diploid cells containing GAL3A368V and a-syn or vector were precultured in 
medium containing 2% glucose overnight. Cultures with an OD600 of 8–14 were washed 
twice with water and transferred to galactose and glycerol-ethanol conditions beginning 
at an OD600 of 1.0. The cells were induced for 6 and 18 h. OD600 was measured and 
recorded at the two time points, and 107 cells were diluted to a total volume of 1 mL. 
Next, 100 µL of the diluted culture was isolated and mixed with 900 µL distilled water. 
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Of this mixture, 10 µL was diluted with 990 µL water. For strains containing a-syn, 100 
µL of the mixture was plated onto YPD and YPGE agar plates. Of the remaining mixture, 
100 µL was diluted in 900 µL water. For strains with and without a-syn, 100 µL of this 
final mixture was plated onto both YPD and YPGE agar plates. Thus, for all strains, we 
plated a 10-5 dilution of the original culture, and for a-syn strains, in addition to a 10-5 
dilution, we also plated a 10-4 dilution of the original culture. The a-syn strain was toxic 
under glycerol-ethanol growth conditions; therefore, we used two dilution factors for a-
syn strains as we expected that a single digit colony count may give erroneous results. 
Including a 10-4 dilution for a-syn strains enabled corroboration of the colony counts 
recorded at the 10-5 dilution. After plating, the agar plates were incubated in a stationary 
incubator at 30 °C for 3 d for YPD and 4 d for YPGE. Single colonies were counted by 
visualization, and numbers were recorded. The number of colonies in YPD plates 
represented cells that were viable, and the number of colonies in YPGE plates 
represented cells that were respiratory-competent. For a-syn, when deciding whether to 
use the counts from the 10-4 or 10-5 dilutions, we chose the one nearest to 100. This 
colony count was then multiplied by the dilution factor, and statistical analyses was 
performed using the final derived number. 
Reactive oxygen species quantification 
Diploid yeast cells containing a-syn and GAL3A368V (1 × 107 cells) were harvested 
and centrifuged at 3600 rpm for 5 min after induction in galactose and glycerol-ethanol at 
3, 6, and 18 h. ROS was measured using dihydroethidium (DHE),83 which was dissolved 
in 500 µL of selective medium, added to the centrifuged cells, and incubated at room 
temperature (23 + 2 °C) for 20 min in the dark. Cells were then centrifuged and washed 
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twice with phosphate-buffered saline, and 160 µL of cells was added to black flat-
bottomed CoStar plates. Using a plate reader (Fisher Scientific, Ontario, Canada), the 
density of the cells was measured at an OD600, and the absorbance was measured at lex = 
485 nm and lem = 620 nm.84 The amount of ROS was calculated as the ratio of the 
measured absorbance to OD600. The same volume of cell solution (3 µl) was used for 
microscopic imaging in the Tx Red channel for visual analysis and qualitative assessment 
of ROS. 
Split green fluorescent protein system and oligomer engineering 
DNA was prepared by digesting pRS416-GAL-ccdB-DsRed and pRS426-GAL-
ccdB-DsRed with HindIII and SlaI (or XhoI), removing the Ds Red tag and purifying the 
vector. Forward and reverse primers for GFP11 were diluted to 100 µM and then further 
to 1 µM. Next, 50 µL of forward and reverse primers were combined and placed in 
boiling water for 10 min. The mixture was then allowed to cool completely to room 
temperature for 1 h to allow annealing, 1 µL of the mixture was then diluted 10-fold, and 
DNA ligation was performed. The ligation mixture had a total volume of 10 µL, 
including 1 µL T4 ligase, 1 µL oligomer mixture (obtained previously), 1 µL T4 ligase 
buffer, and 100–150 ng of digested linearized pRS416-Gal-ccdB or pRS426-Gal-ccdB. 
This mixture was then transformed into T1K Escherichia coli bacteria and plated on 
lysogeny broth agar plates containing carbenicillin. DNA was extracted from the bacterial 
cells and confirmed by restriction digestion. An LR reaction was then performed to 
individually insert the entry clones, SNCA, TOM6, and CIT1, into the destination vectors 
of pRS416-GAL-ccdb-GFP11 and pRS426-GAL-ccdb-GFP11. The plasmid constructs 
were confirmed at each step by restriction digestion and sequencing. Subsequently, the 
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gateway vector was transformed into W303 MATa yeast integrated with p404-MTS 
mCherry plasmid. The W303 MATa yeast strain containing GAL3A368V was mated with 
the W303 MATa yeast strain containing p404-MTS-mCherry and SNCA. Since we did not 
observe a green color with any of the three strains, we further examined the genetic code 
of the plasmids. We noticed the presence of a stop codon in the reading frame of both 
plasmid constructs that may have prevented the transcription of GFP11. We also noticed a 
glycine-rich coding sequence between the gene and GFP11 that may have caused hairpin 
formation. To remove the stop codon and glycine sequences, we performed Yeast Gap 
Repair.85 First, PCR was performed using primers (Table 3) to synthesize the gene and 
GFP11 while removing the intervening stop codon and glycine. Second, pRS416GAL-
SNCA-GFP11 and pRS416GAL-CIT1-GFP11 were cut using HindIII enzyme, whereas 
pRS416GAL-TOM6 GFP11 was cut using EcoRI enzyme. The cut plasmid was then 
purified, and 400 ng of purified plasmids was mixed with 100 ng of PCR product; using a 
one-step yeast transformation, this mixture was transformed into W303 MATa yeast that 
had an integrated p404-MTS mCherry plasmid. Using the PCR product as template, the 
yeast repairs the gap in the cut plasmid construct. The final plasmid product contained the 
gene and GFP11, without the intervening stop codon and glycine sequences. The construct 
was confirmed by restriction digestion, however, still required confirmation via 
sequencing. 
Human gene plasmid library and transformation into yeast 
The Ju and Zhong laboratory generated a human gene library containing 14,827 
sequence-verified individual human gene open reading frames (ORFs) (corresponding to 
12,890 human genes) cloned into the destination vector pRS416GAL-ccdB (URA 
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marker) in the W303 MATa yeast that contained an integrated IntTox SNCA (Table 1). 
Plasmid DNA in the destination vector was stored frozen at -80 °C. A high-throughput 
yeast transformation protocol86 was used to transform all the plasmid DNA. Transformed 
yeast were saved as glycerol stocks and stored at -80 °C. 
High-throughput screening 
IntTox a-syn strain containing the human genes and strain containing GAL3A368V 
were grown separately in selective glucose media overnight in 96-well plates. After 
overnight growth, we used pins to cross the two strains in YPD media and grew the yeast 
overnight. The grown culture was transferred using pins to a triple selective glucose 
media and grown for 48 h. The culture was then spotted onto triple selective glucose and 
glycerol-ethanol agar plates using the bench-top RoToR HDA robot (Singer Instruments, 
Roadwater, UK). The robot spots four times for each well; thus, in the agar plate there 
were a total of 384 spots. The agar plates were incubated in 30 °C for 2 d (for glucose 
plates) and 5 d (for glycerol-ethanol plates) when the images were taken using a Canon 
EOS 200D camera (Peschiera Borromeo (Mi), Italy). 
Confirmation of genetic hits 
Four types of scoring by visual examination of the agar plates were used: trace, 
mild, moderate, and strong. The original human gene plasmid of the hits was revived 
from the bacterial glycerol stock. The bacteria were grown in lysogeny broth with 
carbenicillin and isolated using a plate miniprep technique (GenScript 96-well Plasmid 
Miniprep Kit, New Jersey, USA). Next, 1.3 mL medium containing antibiotics was added 
to 96-well plates. Bacteria were inoculated in the medium using pins to transfer the 
glycerol stock into the new medium. The plates were covered with adhesive tape and 
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grown overnight at 37 °C in a shaking incubator until an OD600 between 1–4 was 
reached. The cells were then harvested by centrifugation at 2500 rpm for 10 min, and 250 
µL of resuspension solution with RNase A was added to each well, followed by vigorous 
vortexing. Next, 250 µL lysis solution was added to each well and thoroughly mixed, and 
250 µL neutralization solution was then added. The plates were inverted multiple times 
until a clear precipitate was formed. The plates were centrifuged, the supernatants were 
transferred to new 96-well filter plates, and the plates were centrifuged again. Filtered 
lysates were then transferred to a binding plate and centrifuged at 2500 rpm for 10 min. 
The flow-through was then placed on a new deep-well plate, and 500 µL of wash solution 
with ethanol was added. The samples were then centrifuged to remove residual wash 
solution. The binding plate was placed on top of the collection plate and 50 µL elution 
solution was added. After incubation at room temperature for 2 min, the plate was 
centrifuged at 2500 rpm for 5 min. Each plasmid containing human gene clones was then 
individually transformed into the IntTox a-syn W303 MATa strain using a standardized 
yeast one-step transformation protocol and plated on double selective agar plates. After 
allowing cells to grow at 30 °C for 4 d, the cells were isolated, grown in double selective 
medium, and mated with the GAL3A368V allele from the opposite mating type. The toxicity 
was confirmed after individually spotting the diploid strains. 
Gene ontology analysis 
Gene ontology (GO) enrichment analysis was performed using the analysis tool 
found at http://geneontology.org. The software that runs the analysis is called the 
PANTHER Classification System, (http://www.pantherdb.org/) which is maintained up to 
date with GO annotations. This is a comprehensive system that combines data from 82 
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complete genomes and their phylogenetic trees. The statistical model that is used for GO 
analysis is the hidden Markov models.87 Results from this analysis will provide 
information on which GO terms are overrepresented or underrepresented using 
annotations for that gene set. The gene IDs of the IntTox a-syn toxicity suppressors along 
with the entire list of human gene clones from the library (reference list) were used for 
the analysis; duplicate genes were deleted prior to analysis. Three GO aspects - molecular 
function, biological process and cellular component were set for the analysis. GO terms 
shared by the suppressor list were compared to the background distribution of annotation. 
The closer the p value was to zero, the more significant the GO term associated with the 
group of genes was determined to be. A Fischer’s exact test was used and a Bonferroni 
correction for multiple testing was selected. Only results that were Bonferroni-corrected 
for p < 0.05 are displayed. 
Statistical analyses 
The data presented in figures as bars represent means + standard errors of the 
means (SE). Experiments were performed independently a minimum of three times. 
Where necessary, a natural log transformation was performed to correct for violation of 
the assumption of constant variance between groups. For analysis including different time 
points, interactions between genes and times were assessed first before measuring 
differences between genes and controls. The differences between a-syn and controls 
were assessed by one-way analysis of variance (ANOVA), two-way ANOVA, repeated 
measure ANOVA, or Type III tests of fixed effects. To compare the suppressors of a-syn 
with the vector, Dunnett’s test was performed. Results with p values < 0.05 were 
considered significant. Analyses were performed using SAS (v. 9.4) software.  
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Table 1. Yeast strains 
Strain Genotype Reference 
W303  MATa can1−100 his3−11,15 leu2−3,112 
trp1−1 ura3−1 ade2−1 
 
W303 MATa can1−100 his3−11,15 leu2−3,112 
trp1−1 ura3−1 ade2−1 
 
NoTox a-syn 
(1 copy of a-syn) 
α–syn-WT, MATa can1−100 his3−11,15 




(4–5 copies of a-
syn) 
α–syn-WT, MATa can1−100 his3−11,15 





(> 6 copies of a-
syn) 
α–syn-WT, MATa can1−100 his3−11,15 




1X FUS FUS-WT, MATa can1−100 his3−11,15 
leu2−3,112 trp1−1 ura3−1 ade2−1 
pRS303-GAL-FUSWT 
89 
2X TDP-43 TDP-43-WT, MATa can1−100 his3−11,15 




HTT103Q HTT103Q, MATa can1−100 his3−11,15 






Table 2. Plasmids 
Plasmid Reference  
pRS303-GAL1-ccdB (HIS3)  89 
pRS415-GPD-ccdB (LEU2) This study 
pRS415-GPD-GAL3 (LEU2) This study 
pRS415-GPD-GAL4 (LEU2) This study 
pRS415-GPD-GAL3-A368V (LEU2) This study 
pRS415-GPD-GAL3-F237Y (LEU2) This study 
pRS415-GPD-GAL3-S509P (LEU2) This study 
pRS415-GPD-GAL3-A368V- F237Y (LEU2) This study 
pRS415-GPD-GAL3-F237Y- S509P (LEU2) This study 
pRS415-GPD-GAL3-S509P-A368V (LEU2) This study 
pRS415-GPD-GAL3-S509P-A368V-F237Y (LEU2) This study 
pRS303-LacZ (HIS3) Addgene 
pRS416-GAL1-1433b (URA3) This study 
pRS416-GAL1-1433q (URA3) This study 
pRS416-GAL1-1433g (URA3) This study 
pRS416-GAL1-1433z (URA3) This study 
pRS416-GAL1-1433s (URA3) This study 
pRS416-GAL1-1433h (URA3) This study 
pRS416-GAL1-GLRX1 (URA3) This study 
pRS416-GAL1-TM39B (URA3) This study 
pMitoLoc-preCOX4-mCherry & preSU9-GFP Addgene 
pMitoLoc-preCOX4-mCherry & preSU9-TFP This study 
p404-Grx5-GFP1-10 99 
p404-MTS-mCherry- GFP1-10 99 
pRS416-GAL1-ccdB-DsRed (URA3) This study 
pRS416-GAL1-GFP11-SNCA (URA3) This study 
pRS416-GAL1- GFP11-TOM6 (URA3) This study 
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pRS416-GAL1- GFP11-CIT1 (URA3) This study 
pRS426-GAL1-ccdB-DsRed (URA3) This study 
pRS426-GAL1- GFP11-SNCA (URA3) This study 
pRS426-GAL1- GFP11-TOM6 (URA3) This study 
pRS426-GAL1- GFP11-CIT1 (URA3) This study 
pRS416-GAL1-ccdB- GFP11 (URA3) This study 
pRS426-GAL1-ccdB- GFP11 (URA3) This study 




Table 3. Primers 











































III AIM 1: TO DEVELOP A METHOD OF GENE OVEREXPRESSION UNDER 
NON-GALACTOSE CONDITIONS USING GAL3 ALLELES 
 
Rationale 
Yeast genetic screening has identified key biological pathways of many 
neurodegenerative disease-related genes including SNCA,42,64,88 FUS,89 and HTT.64,90 
SNCA mutations cause Parkinson’s disease, FUS mutations cause amyotrophic lateral 
sclerosis (ALS), and mutations in HTT cause Huntington’s disease. However, all prior 
screening studies have been performed under galactose-enriched growth condition, 
exclusively. Furthermore, mutations in SNCA, FUS, and HTT cause mitochondrial 
dysfunction, which is associated with disease pathology. Additionally, calorie restriction, 
in yeast and animal models, has been shown to delay neurodegeneration.91,92 Autophagy, 
a mechanism of recycling obsolete cellular constituents has also been widely studied in 
neurodegenerative disorders. Specifically, attenuation of autophagy has been shown to 
initiate development of Parkinson’s disease;93,94 while induction of autophagy delays 
progression of ALS.95 As discussed previously, mitochondria can be studied under a 
respiratory glycerol condition, and calorie restriction, in yeast, can be induced by 
reducing the concentration of glucose in the growth medium. Further, autophagy can be 
induced by depleting the medium of nitrogen.96,97 We analyzed a method that would 
enable the study of genes under these non-galactose conditions. As such, we sought to 
test and validate a novel overexpression system that involved constitutive GAL3 alleles 
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that can induce GAL1 promoter in non-galactose conditions.75 These alleles were 
integrated into a haploid yeast strain where the WT GAL3 was knocked down.. Since our 
laboratory previously designed a diploid screening method,98 here we determined if the 
GAL3 alleles were capable of inducing the GAL1 promoter in diploid yeast strains 
without the deletion of two WT GAL3 genes.  
Experimental design 
GAL1 promoter and GAL3 alleles. We chose one intermediate strength and two strong 
GAL3 alleles from the previous publication.75 Three mutations in the GAL3 gene (F237Y, 
A368V, and S509P) were generated by site-specific mutagenesis using the pRS415-GPD 
vector (LEU marker) and transformed into the WT yeast strain W303 MATa. We also 
generated double- and triple-combination mutants (F237Y+A368V, F237+S509P, 
A368V+S509P, and F237+A368V+S509P).  
b-galactosidase assay. We used b-galactosidase assays to quantify the induction of the 
GAL1 promoter under 2% glucose, 2% galactose, 3% glycerol with 1% ethanol, 2% 
raffinose, calorie restriction (0.5% and 0.1% glucose), and nitrogen starvation (2% 
raffinose and 2% glucose) conditions. b-galactosidase, a widely used reporter gene, 
hydrolyzes o-nitrophenyl-b-D-galactopyranoside to o-nitrophenol and galactose, resulting 
in a yellow color. The intensity of the yellow color was determined by measuring the 
A420. An LR reaction was performed to synthesize the pRS303-LacZ plasmid. We then 
performed a high efficiency yeast transformation to integrate the pRS303-LacZ plasmid 
(HIS marker) into the WT yeast strain W303 MATa.  
Mating strategy to perform b-galactosidase assays. We grew GAL3 alleles (MATa) and 





Figure 2. Schematic representation of the mating strategy used in this study. 
Mating of the b-galactosidase gene under the GAL1 promoter and the GAL3 alleles to 
measure b-galactosidase activity. We used three GAL3 alleles (GAL3F237Y, GAL3A368V and 
GAL3S509P) or their combinations for the experiments in Aim 1. The b-galactosidase gene 
was integrated into the haploid MATa yeast strain chromosome, whereas the GAL3 
alleles were transformed into the haploid opposite mating type MATa yeast strain using a 
constitutive promoter, pRS415-GPD (Table 2). Single colonies of two haploid yeast 
(W303 MATa containing b-galactosidase enzyme and W303 MATa containing GAL3 
alleles) were crossed in YPD agar plates and allowed to grow overnight. The yeast patch 
from the crossed area was picked and streaked on double selective agar plates and 
incubated for 2–3 days to isolate a single colony. The resulting diploid yeast contained 
both the b-galactosidase gene and the GAL3 alleles.  
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cells to double-selection 2% glucose medium and grew them overnight. The cells were 
then washed and transferred to double selective medium containing different carbon 
sources beginning at an OD600 of 0.1. The diploid yeast strains were permitted to grow to 
mid-log phase, at which point the experiment was conducted.  
Results 
1.1: To develop and test a method of gene overexpression under non-galactose 
conditions  
GAL3 alleles induce the GAL1 promoter under non-galactose conditions in the 
absence of glucose. Figure 3 shows the results of b-galactosidase assays for the control, 
WT GAL3, and GAL3 alleles - GAL3F237Y, GAL3A368V, and GAL3S509P. b-galactosidase is 
under the control of the GAL1 promoter; thus, higher the enzyme activity results in higher 
promoter induction. Glucose served as the negative control, while galactose as the 
positive control. GAL3F237Y, GAL3A368V and GAL3S509P exhibited significantly higher 
induction under glycerol-ethanol compared to the vector control (all p < 0.0001). For the 
spotting assays, we initially analyzed the genes in a glycerol-rich growth condition and 
observed that the cells expressing a-syn exhibited growth only after five days of 
incubation. Hence, we supplemented the media with 1% ethanol to aid the cells in more 
rapid growth. Only GAL3S509P exhibited significantly (p = 0.008) higher induction under 
nitrogen starvation compared to the vector control. However, under calorie restriction 
conditions, none of the alleles showed significant induction when compared to the 
control. Since all three alleles exhibited significant induction in the glycerol-ethanol 
condition, we hypothesized that the combination of allele mutants will elicit a more 




 Figure 3. GAL3F237Y, GAL3A368V and GAL3S509P induce GAL1 promoter under 
glycerol-ethanol.  
Single diploid yeast colonies containing both the b-galactosidase enzyme (W303 MATα 
strain) and GAL3 alleles (W303 MATa strain) were grown overnight in double selective 
2% glucose media. The pre-culture (OD600 of 8–14) was washed twice with distilled 
water and inoculated into media lacking histidine (gene) and leucine (GAL3 vector) 
beginning at an OD600 of 0.1. Media consisted of 2% glucose (negative control), 2% 
galactose (positive control), 3% glycerol with 1% ethanol, nitrogen starvation containing 
2% glucose, and calorie restriction containing 0.5% glucose. The culture was grown until 
mid-log phase when the cells were isolated. The intensity of the yellow color was 
measured at A420. b-galactosidase activity of GAL3WT, GAL3F237Y, GAL3A368V and 
GAL3S509P was compared to the empty vector (pRS415-GPD) in each condition by two-
way ANOVA. * p < 0.05 and hence significantly different compared to control; N.S, no 


































Combining GAL3 alleles do not induce the GAL1 promoter under non-galactose 
conditions. Interestingly, neither the double- nor the triple-combination mutants (Figure 
4) induced the GAL1 promoter. Gal3p regularly transitions between the ‘open inactive’ 
and ‘closed active’ conformation, and the GAL3 alleles induce the ‘closed active’ 
conformation even under non-galactose conditions.73 However, the results of this 
experiment suggest that the combination of alleles fails to induce the ‘closed active’ 
conformation. Hence, we performed structural analysis of the position of alleles and their 
combinations in relation to the ‘transition site’ or the ‘switch region’ (Figure 5). We 
found that F237 formed hydrophobic bonds and was located adjacent to the ‘switch’ 
region; a mutation in this position enabled transition to a ‘closed active’ conformation. 
The combination of F237Y and S509P showed a mutual negating effect of the closed 
conformation, likely caused by disruption of the b-sheet formation at S509. Thus, the 
allele combinations likely inhibited transition to the ‘closed active’ conformation, thereby 
preventing its constitutive action. 
 
1.2: To test a gene overexpression method using neurodegenerative disease gene 
models and GAL3 alleles 
GAL3A368V and GAL3F237Y induce GAL1 promoter under glycerol-ethanol. We sought 
to identify the strongest inducer among the three GAL3 alleles using IntTox a-syn under 
glycerol-ethanol growth conditions. We chose the IntTox a-syn as this strain exhibits 
toxicity when induced in galactose under haploid conditions. Hence, a phenotypic change 
in glycerol-ethanol condition would be readily detectable. Here, we created a diploid 




Figure 4. Combinations of GAL3F237Y, GAL3A368V and GAL3S509P do not induce GAL1 
promoter in non-galactose conditions.  
Double and triple mutations of the alleles were generated using PCR as described in the 
methods. Single diploid yeast colonies containing both b-galactosidase enzyme (W303 
MATα strain) and GAL3 allele combinations (W303 MATa strain) were grown overnight 
in double selective 2% glucose media. The pre-culture (OD600 of 8–14) was washed twice 
with distilled water and inoculated into five different media lacking histidine (gene) and 
leucine (GAL3 vector) starting at OD600 of 0.1: 2% glucose (negative control), 2% 
galactose (positive control), 3% glycerol with 1% ethanol, nitrogen starvation containing 
2% glucose, and calorie restriction containing 0.5% glucose. The culture was grown until 
mid-log phase when the cells were isolated, and the assay was performed. The intensity 
of the yellow color was measured at A420. b-Galactosidase activity of GAL3 allele 
combinations was compared to the empty vector in each condition by two-way ANOVA. 
N.S, no significant difference compared to control; WT, wild-type.   
GAL3F237Y - + + - +
GAL3A368V - + - + +

































Figure 5. Combination of GAL3F237Y and GAL3S509P fails to enable transition to 
‘closed active’ Gal3p conformation. 
(A) Position of the F237, A368 and S509 in relation to the ‘Open-Closed Pivot’ in Gal3p. 
The structure on the top of the figure is the Gal3p which, in its closed conformation, 
binds to the transcriptional repressor, Gal80p (gray colored structure in the bottom of the 
figure). A368 is located at the transition site, which is the region where the galactose 
binds and the conformation switches from ‘open inactive’ to ‘closed active’. (B) F237 
forms hydrophobic bonds and is located adjacent to the ‘Switch’ region; a mutation in 
this position causes transition to a closed conformation. A mutation in S509 disrupts the 
adjacent β-sheet and initiates a closed conformation. However, the combination of F237 
and S509 fails to enable the transition, likely due to the mutual cancelling effect caused 
by disruption of the hydrophobic bonds and the β-sheet.  
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performed in diploid conditions. The diploid strain was plated onto double selective  
glucose (negative control), galactose (positive control) and glycerol-ethanol agar plates. 
Two primary findings were observed (Figure 6). First, the IntTox a-syn was no longer 
toxic under galactose condition. The only difference between previous IntTox a-syn 
studies showing toxicity in galactose and our study is that previously, IntTox a-syn was 
tested in haploid state while our study was performed in diploid state. Second, GAL3F237Y 
and GAL3A368V induced IntTox a-syn under glycerol-ethanol condition and elicited 
toxicity. Alternatively, GAL3S509P did not cause toxicity to IntTox a-syn although we saw 
significant induction of the GAL1 promoter in the b-galactosidase assay (Figure 3). As 
expected, GAL3WT and the empty vector did not induce the gene, corroborating the 
findings of the b-galactosidase assay. Taken together the results from the spotting and b- 
galactosidase assays suggest that both GAL3A368V and GAL3F237Y induced the GAL1 
promoter in glycerol-ethanol. Among the two, we chose GAL3A368V for the next 
experiments. 
GAL3A368V does not induce toxicity of neurodegenerative disease-genes in the presence 
of glucose. We next wanted to determine if GAL3A368V effectively induces genes in non-
galactose conditions other than glycerol, and if so, whether it causes toxicity. Four 
neurodegenerative disease-related genes, SNCA (IntTox and HiTox), FUS, TDP-43, and 
HTT103Q were chosen, all of which have been shown to cause cellular toxicity under 
galactose condition. We generated a diploid yeast containing the genes and GAL3A368V 
and plated the cells under double selective nitrogen starvation and calorie restriction 
conditions. Nitrogen starvation conditions (activate autophagy) lacks ammonium sulfate 





Figure 6. GAL3A368V and GAL3F237Y induce toxicity of IntTox a-synuclein under 
glycerol-ethanol. 
Single diploid yeast colonies containing empty vector (pRS303-GAL) or IntTox a-syn 
(W303 MATa strain) and empty vector or GAL3 alleles (W303 MATα strain) were grown 
overnight in double selective 2% glucose media lacking histidine (gene) and leucine 
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(GAL3 vector). The culture was washed twice with distilled water and diluted to an OD600 
of 1.0 and was spotted (left-most column). The diluted culture was further serially diluted 
10-fold and spotted four times; the dilution was repeated until the last column on the 
right. The dilution is indicated by the tapering triangle bar on the top. Cells were then 
spotted onto solid double selective agar plates containing 2% glucose (negative control), 





neurodegeneration) has a reduced media glucose content of 0.5%. Under both conditions  
with all four genes, no toxicity was observed (Figure 7).  
 
1.3: To assess the toxicity, aggregate formation and expression level of IntTox and 
HiTox a-synuclein under non-galactose conditions using integrated GAL3A368V allele. 
GAL3A368V induces the GAL1 promoter in the presence of 0.1% glucose and raffinose. 
We integrated the GAL3A368V allele into the yeast genome and performed b-galactosidase 
assays. We chose conditions that had not been tested previously. In the calorie restriction 
condition, since 0.5% glucose did not allow for GAL1 promoter induction, we now 
reduced the amount of glucose to 0.1%. In addition, we tested raffinose and nitrogen 
starvation. Raffinose is an alternate carbon source that undergoes partial oxidative 
phosphorylation. GAL3A368V significantly increased b-galactosidase activity under calorie 
restriction (p = 0.01), raffinose (p < 0.0001), and nitrogen starvation (p < 0.0001) 
compared to the vector (Figure 8). Thus, we concluded that GAL3A368V can induce GAL1 
promoter in non-galactose conditions provided the glucose content is relatively low. 
IntTox and HiTox a-syn overexpression cause toxicity under non-galactose conditions. 
Since GAL1 promoter induction was observed in the above conditions, we next tested the 
IntTox and HiTox a-syn cellular phenotypes in these conditions. Glucose served as the 
negative control and galactose, the positive control (Figure 9). Neither IntTox nor HiTox 
a-syn induced toxicity under calorie restriction condition. We know that GAL1 promoter 
is induced in this condition (Figure 8). Both IntTox and HiTox a-syn showed toxicity 
under raffinose and nitrogen starvation. The addition of nitrogen starvation to raffinose 




Figure 7. GAL3A368V does not induce toxicity of neurodegenerative disease-related 
genes in the presence of glucose.  
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Single diploid yeast colonies containing both empty vector (pRS303-GAL), IntTox and 
HiTox a-syn, FUS, TDP-43 or HTT103Q (W303 MATa strain) and empty vector 
(pRS415-GPD) or GAL3 alleles (W303 MATα strain) were grown overnight in double 
selective 2% glucose media. The culture was washed twice with distilled water and 
diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture was 
further serially diluted 10-fold and spotted four times; the dilution was repeated until the 
last column on the right. The dilution is indicated by the tapering triangle bar on the top. 
Cells were then spotted onto solid double selective agar plates containing 2% glucose 
(negative control), 2% galactose (positive control), nitrogen starvation (2% glucose) or 





Figure 8. GAL3A368V induces the GAL1 promoter under calorie restriction and 
nitrogen starvation conditions. 
GAL3A368V was integrated into the yeast genome using a high efficiency yeast 
transformation protocol. Single diploid yeast colonies containing both b-galactosidase 
enzyme (W303 MATα strain) and GAL3A368V (W303 MATa strain) were grown overnight 
in double selective 2% glucose media. The culture was washed twice with distilled water 
and inoculated into five different media lacking histidine (gene) and leucine (GAL3 
vector) starting at OD600 0.1: 2% glucose (negative control), 2% galactose (positive 
control), calorie restriction (0.1% glucose), 2% raffinose, and nitrogen starvation (2% 
raffinose). The culture was grown until mid-log phase when the cells were isolated, at 
which point the assay was performed. The intensity of the yellow color was measured at 
A420. b-galactosidase activity of GAL3A368V was compared to the empty vector in each 
condition by two-way ANOVA. * p < 0.05 and, hence, significantly different compared 
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Figure 9. IntTox and HiTox a-synuclein overexpression cause toxicity under non-
galactose conditions.  
Single diploid yeast colonies containing both empty vector (pRS303-GAL), IntTox a-
syn, or HiTox a-syn (W303 MATa strain) and empty vector (pRS415-GPD) or GAL3A368V 
(W303 MATα strain) were grown overnight in double selective 2% glucose media. The 
culture was washed twice with distilled water and diluted to an OD600 of 1.0 and was 
spotted (left-most column). The diluted culture was further serially diluted 10-fold and 
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spotted four times; the dilution was repeated until the last column on the right. The 
dilution is indicated by the tapering triangle bar on the top. Cells were then spotted onto 
solid double selective agar plates containing 2% glucose (negative control), 2% galactose 
(positive control), calorie restriction (0.1% glucose), 2% raffinose, and nitrogen 




interesting is the absence of toxicity in HiTox a-syn cultures in calorie restriction 
condition, while toxicity was present in IntTox a-syn cultures containing raffinose, as 
these findings are in stark contrast to those previously observed for galactose.65 Hence, 
this study highlights the necessity of studying a-syn in non-galactose conditions and 
validates the use of GAL3A368V performing the same. 
IntTox and HiTox a-syn toxicity do not correlate with the presence of aggregates 
under non-galactose conditions. Toxicity of IntTox and HiTox a-syn often correlates 
with the presence of aggregates in yeast.65 Since we observed toxicity of the two strains 
in the spotting assay, we next sought to examine a-syn aggregates under the same 
conditions. Under calorie restriction, no IntTox a-syn aggregates were observed, 
however, those of HiTox a-syn were evident (Figure 10 and 11). Under raffinose and 
nitrogen starvation conditions, we saw similar patterns with aggregates only being 
formed by HiTox a-syn, not IntTox a-syn (Figure 10 and 11). When comparing the 
results of the spotting assay and microscopic aggregates, two interesting findings become 
apparent. First, although IntTox a-syn was toxic under raffinose conditions, no 
aggregates were formed. Second, HiTox a-syn was not toxic under calorie restriction but 
aggregates were formed. Thus, non-galactose conditions serve to define a new paradigm 
shift were toxicity produced by a-syn does not necessarily correlate with the presence of 
aggregates. The next logical question was whether the expression levels of a-syn under 
non-galactose conditions are responsible for the observed differences in toxicity and 
aggregation.  
Although verification of expression levels across growth conditions require 
further experimental repeats, IntTox a-syn did not seem to exhibit different expression 
48 
 
levels in the non-galactose growth conditions compared to that in galactose. HiTox a-syn 
seemed to show higher expression levels in calorie restriction, raffinose and nitrogen 
starvation conditions (Figure 12). In either situation, the results do not explain the 
increased toxicity of IntTox a-syn in raffinose conditions nor the reduced toxicity of 
HiTox a-syn in calorie restriction conditions. It, therefore, appears that the toxicity is not 






Figure 10. IntTox a-synuclein does not form aggregates under non-galactose 
conditions.  
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0 
and was grown in double selective media of four types: 2% galactose, calorie restriction 
(0.1% glucose), raffinose and nitrogen starvation (2% raffinose), and induced for 4, 6 and 
8 h. At each time point, the cells were isolated and 3 µL of suspension was placed on a 







Figure 11. HiTox a-synuclein forms aggregates under non-galactose conditions.  
Single diploid yeast colonies containing both HiTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0 
and was grown in four different types of double selective media: 2% galactose, calorie 
restriction (0.1% glucose), raffinose and nitrogen starvation (2% raffinose), and induced 
for 4, 6 and 8 h. At each time point, the cells were isolated and 3 µL of suspension was 
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Figure 12. HiTox a-synuclein expression increases while IntTox a-synuclein 
expression is unaffected under non-galactose conditions. 
Single diploid yeast colonies containing both IntTox a-syn, or HiTox a-syn (W303 
MATa strain) and empty vector (pRS415-GPD) or GAL3A368V (W303 MATα strain) were 
grown overnight in double selective 2% glucose media. The culture was washed twice 
with distilled water and diluted to an OD600 of 1.0 and was grown in four different types 
of double selective media: 2% galactose, calorie restriction (0.1% glucose), raffinose and 
nitrogen starvation (2% raffinose). The cultures were then induced for 6 h after which 
point the protein was extracted. SNCA encoding IntTox a-syn, or HiTox a-syn were 
tagged with YFP and, hence, an antibody against GFP was used. PGK1 was used as the 
loading control protein. (A) shows the blotting images and (B) shows quantification of 
the bands. Image quantification was performed using ImageJ. The experiment was 
repeated twice, and the bar graphs represent mean + SE. Protein expression in galactose 









IV. AIM 2: TO EXAMINE THE ROLE OF MITOCHONDRIA IN a-SYNUCLEIN 
TOXICITY UNDER GLYCEROL-ETHANOL 
Rationale 
When a-syn was induced under non-galactose conditions, variations were 
observed in the toxicity levels, presence of aggregates and protein expression. For this 
study, we focused on the glycerol-ethanol condition, which is a non-fermentable carbon 
source for yeast and thus requires a fully functional mitochondria for survival. We know 
that mitochondrial dysfunction causes Parkinson’s disease, and a-syn affects the 
mitochondria by inhibiting complex I activity and causing mitochondrial fragmentation. 
Since we observed higher toxicity of a-syn in glycerol-ethanol compared to galactose, we 
sought to better understand the underlying mechanisms related to this new phenotype. 
Since mitochondria appears to be vital in glycerol metabolism, we focused on studying 
the respiratory competency of the cells, mitochondrial structure and membrane potential, 
as well as ROS production.  
Experimental design 
Spotting assay. The strains that were used include NoTox a-syn (1 copy of SNCA), 
IntTox a-syn (4–5 copies of SNCA), and HiTox a-syn (> 6 copies of SNCA). We also 
assessed the toxicity of two ALS disease-associated genes: FUS and TDP-43. For this 
Aim, SNCA, FUS, and TDP-43 were transformed into the W303 MATa of yeast (Table 
1), and GAL3A368V was transformed into the opposite mating type W303 MATa. Without 
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mating, we also spotted the genes on galactose and glycerol-ethanol plates under haploid 
conditions (without GAL3A368V).  
Measurement of aggregates and examination of mitochondria. We used IntTox a-syn 
strain tagged with YFP for microscopic examination of aggregates; while pMitoLoc was 
used to simultaneously examine total and healthy mitochondria. For both measurements, 
diploid yeast strains containing IntTox a-syn and GAL3A368V were precultured in 2% 
glucose medium overnight. Cultures with an OD600 between 8–14 were then washed and 
resuspended in selective galactose or glycerol-ethanol medium. The starting OD600 was 
1.0 and the suspended medium was incubated for 3–18 h. Aggregates were visualized 
with the YFP channel and mitochondria were visualized with the CFP and Tx Red 
channels.  
Measurement of ROS. After induction for 3, 6 and 18 h, cells were isolated and 
incubated with DHE for 20 min. The amount of red fluorescence was directly 
proportional to the amount of ROS produced. Diploid yeast strains containing IntTox a-
syn and GAL3A368V were used.  
Mitochondrial targeting of a-synuclein. We used a split GFP system for this 
experiment.99 SNCA was cloned with the 11th b-strand of GFP (GFP11). If SNCA (cloned 
to GFP11) reconstitutes with GFP1-10, which contain mitochondrial targeting sequences, 
we would expect to see green fluorescence emitted from the reconstituted GFP. 
Results 




IntTox a-syn is toxic under glycerol-ethanol but not under galactose condition with 
similar expression. A single copy of SNCA (NoTox a-syn), 4–5 copies of SNCA (IntTox 
a-syn), and > 6 copies of SNCA (HiTox a-syn), FUS and TDP-43 (Table 1) were 
transformed into the MATa yeast strain W303; while GAL3A368V, was transformed into the 
MATa yeast strain. The toxicity phenotypes of the a-syn diploid strains were detected by 
spotting assays under galactose and glycerol-ethanol agar plates. NoTox a-syn did not 
exhibit toxicity under either condition (Figure 13). Alternatively, IntTox a-syn was toxic 
under the glycerol-ethanol condition but not toxic under the galactose condition; while 
HiTox a-syn, FUS and TDP-43 were toxic under both conditions.  
We also tested all genes under haploid conditions without GAL3A368V to better 
understand (i) if the glycerol-ethanol condition alone is toxic to the cells and (ii) if a 
phenotypic difference was observable for the genes, between the haploid and diploid 
strains. Results show that without GAL3A368V, no induction under glycerol-ethanol 
conditions was observed (Figure 14); and no toxicity was induced by any of the genes. 
Further, compared to diploid strain spotting, IntTox a-syn exhibited a unique phenotype 
i.e. higher toxicity in the haploid strain. Given these two interesting phenotypes, we 
decided to employ only IntTox a-syn in subsequent experiments. 
The OD600 measurement during the induction of IntTox a-syn in liquid media 
over time corroborated the findings of the spotting assay. Under the glycerol-ethanol 
condition IntTox a-syn was found to be more toxic than galactose (Figure 15). As a 
haploid strain, IntTox a-syn showed toxicity in galactose (blue dotted line), however, no 
induction was observed and thus, no toxicity was present in the glycerol-ethanol (orange 





Figure 13. IntTox a-synuclein is toxic under glycerol-ethanol but not under 
galactose.  
Single diploid yeast colonies containing both empty vector (pRS303-GAL), NoTox a-
syn, IntTox a-syn, HiTox a-syn, FUS, or TDP-43 (W303 MATa strain) and empty vector 
(pRS415-GPD) or GAL3 alleles (W303 MATα strain) were grown overnight in double 
selective 2% glucose media. The culture was washed twice with distilled water and 
diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture was 
further serially diluted 5-fold and spotted four times; the dilution was repeated until the 
last column on the right. The dilution is indicated by the tapering triangle bar on the top. 
Cells were then spotted onto solid double selective agar plates containing 2% glucose 
(negative control), 2% galactose (positive control), or 3% glycerol and 1% ethanol, and 






Figure 14. IntTox a-synuclein is toxic under galactose in haploid condition.  
Single haploid yeast colonies containing empty vector (pRS303-GAL), NoTox a-syn, 
IntTox a-syn, HiTox a-syn, FUS, or TDP-43 (W303 MATa strain) was grown overnight 
in double selective 2% glucose media. The culture was washed twice with distilled water 
and diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture 
was further serially diluted 5-fold and spotted four times; the dilution was repeated until 
the last column on the right. The dilution is indicated by the tapering triangle bar on the 
top. Cells were then spotted onto solid double selective agar plates containing 2% glucose 
(negative control), 2% galactose (positive control), or 3% glycerol and 1% ethanol, and 





Figure 15. IntTox a-synuclein is toxic under glycerol-ethanol but not under 
galactose in diploid yeast strains.  
Three yeast strains were used: IntTox a-syn without GAL3A368V (haploid), InTox a-syn 
with empty vector (pRS303-GAL) (diploid control) and IntTox a-syn with GAL3A368V 
(diploid GAL3A368V). Single haploid or diploid yeast colonies were grown overnight in 
double selective 2% glucose media. The culture was washed twice with distilled water 
59 
 
and diluted to an OD600 of 0.1 and resuspended in selective 2% galactose (A) or 3% 




IntTox a-syn was higher in glycerol-ethanol. IntTox a-syn protein levels were similar 
under both conditions (Figure 16A, B). Thus, glycerol-ethanol increased the toxicity of 
neurodegenerative disease-associated genes. However, fluctuations in protein expression 
levels was not responsible for the increased toxicity of IntTox a-syn. 
IntTox a-syn forms aggregates under glycerol-ethanol and not under galactose. Our 
next objective was to examine the aggregate formation of IntTox a-syn in both the 
conditions. IntTox a-syn was tagged with YFP and the diploid strain was induced for 4, 
6, 8, and 18 h. Under the galactose condition, very few aggregates of IntTox a-syn were 
observed before 8 h (Figure 17A), and less than 5% of the cells (Figure 17B) contained 
aggregates at 18 h. Alternatively, under the glycerol ethanol condition, the aggregates 
were visible as early as 6 h and increased steadily until 18 h of induction, at which point, 
approximately 55% of the cells contained aggregates and this percentage was 
significantly higher than that in galactose (p = 0.0001). 
We also examined the aggregates in the haploid strain and found that under 
galactose condition after 18 h of induction, the proportion of cells with aggregates was 
approximately 45% (Figures 18 A and B); while under the glycerol-ethanol condition, 
no induction of IntTox a-syn was observed. Under galactose, the diploid control and 
diploid GAL3A368V had significantly lower (both p < 0.04) number of aggregates 
compared to haploid condition. There was no difference (p = 0.16) between diploid 
glycerol-ethanol and haploid galactose conditions.  
 






Figure 16. Protein expression levels of IntTox a-synuclein do not differ between 
galactose and glycerol-ethanol conditions.  
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0 
and was grown in double selective 2% galactose and 3% glycerol with 1% ethanol. Cells 
from cultures with an OD600 of 1.0 (1 x 107 cells) were isolated at 4, 6, 8 and 18 h of 
induction and the protein was extracted. SNCA encoding IntTox a-syn was tagged with 
YFP and an antibody against GFP was used. The loading control protein used was PGK1. 
(A) shows the blotting images and (B) shows quantification of the bands. Image 
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quantification was performed using ImageJ. The experiment was repeated three times, 
and the bar graphs represent mean + SE. Protein expression at 8 h of induction in 
galactose was used as the reference value. N.S., not significantly different compared to 






Figure 17. Aggregates of IntTox a-synuclein are elevated under glycerol-ethanol 
compared to galactose. 
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Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0 
and was grown in double selective 2% galactose and 3% glycerol with 1% ethanol media, 
and induced for 4, 6, 8 and 18 h. At each time point, the cells were isolated and 3 µL of 
suspension was placed on a glass slide and aggregates were viewed under the YFP 
channel. Scale bar: 5 µm (A). Quantification of the aggregates (B) were performed using 
ImageJ and verified by manual counting. The experiments were repeated three times and 
a minimum of 200 cells were counted for each condition and timepoint. Bars represent 
mean + SE. Repeated measures ANOVAs with a random subject effect was used to 
compare the percentage of cells with a-syn aggregates in galactose and glycerol-ethanol 
at each time points. BF, bright field. *p < 0.05 and hence, significantly different 






Figure 18. Aggregates of IntTox a-synuclein are elevated in haploid galactose and 
diploid glycerol-ethanol yeast strains.  
Three yeast strains were used: IntTox a-syn without GAL3A368V (haploid), InTox a-syn 
with empty vector (pRS303-GAL) (diploid control) and IntTox a-syn with GAL3A368V 
(diploid GAL3A368V). Single haploid or diploid yeast colonies were grown overnight in 
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double selective 2% glucose media. The culture was washed twice with distilled water 
and diluted to an OD600 of 1.0 and was grown in double selective 2% galactose and 3% 
glycerol with 1% ethanol media and induced for 18 h. Cells were isolated and 3 µL of 
suspension was placed on a glass slide. Aggregates were viewed under the YFP channel. 
Scale bar: 5 µm (A). Quantification of the aggregates (B) was performed using ImageJ 
and verified by manual counting. The experiments were repeated three times and a 
minimum of 200 cells were counted for each condition and timepoint. Bars represent 
mean + SE. Two-way ANOVA was used to compare the percentage of cells with a-syn 
aggregates in galactose and glycerol-ethanol conditions. The assumption of constant 
variance was violated, due to two of the groups having values of zero. Satterthwaite’s 
approximation was used to adjust the degrees of freedom to account for this violation. 
Natural log transformation was used for the data before analysis. Since the natural log of 
zero is undefined, a value of 1 was added to all observations. All results are in terms of 




IntTox a-syn reduces both viability and respiratory competency only under glycerol-
ethanol. We first sought to quantify the number of viable and respiratory-competent cells 
in each condition to better understand the increased toxicity in glycerol-ethanol. The 
experiment was performed as explained under Methods (Quantification of viable and 
respiratory-competent cells). Respiratory competency refers to cells having fully 
functional mitochondria and the capacity to grow in glycerol-ethanol condition. We 
expected that IntTox a-syn would induce dysfunction of the mitochondria irrespective of 
the growth condition. Since galactose is a fermentable carbon source that requires 
functional mitochondria for viability, we hypothesized that under galactose, viability 
would not be reduced, however, the respiratory competency would be.  
Figure 19 A and B shows that the viability of the IntTox a-syn was not affected 
in galactose however, it was significantly (p = 0.009 for 6 h and p = 0.04 for 18 h) 
reduced in glycerol-ethanol in the presence of IntTox a-syn. Conversely to what we 
expected, respiratory competency was lower but was not significantly reduced by IntTox 
a-syn in galactose (Figure 19 C), however, was reduced in glycerol-ethanol (Figure 19 
D). We analyzed these results for statistically significant interactions between gene and 
the time required before differences were observed between IntTox a-syn and the 
control; however, we did not observe any interactions, thereby ruling out potential 
skewed results. Hence, we concluded that IntTox a-syn affects viability and respiratory 
competency only under glycerol-ethanol. 
Mitochondria show dense morphology under glycerol-ethanol and disrupted 
membrane potential signal under both galactose and glycerol-ethanol in the presence 





Figure 19. IntTox a-synuclein reduces the number of viable and respiratory-
competent cells only under glycerol-ethanol.  
Single diploid yeast colonies containing both control (pRS303-GAL) or IntTox a-syn 
(W303 MATa strain) and GAL3A368V (W303 MATα strain) were grown overnight in 
double selective 2% glucose media. The culture was washed twice with distilled water 
and diluted to an OD600 of 1.0 and was grown in double selective 2% galactose and 3% 
glycerol with 1% ethanol media, and induced for 6 and 18 h. At an OD600 of 1.0 cells 
were harvested and diluted; for a-syn strain, 100 µL each of 10-4 dilution and 10-5 
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plated on YPD and YPGE agar plates to determine the numbers of viable (A) and 
respiratory-competent cells (B), respectively. Agar plates were incubated for 2 – 3 days 
and single colonies were counted. For a-syn strain, the dilution that provided colony 
counts closer to 100 was chosen. The colony counts for both strains were multiplied by 
the respective dilution factor and used for statistical analysis. Type III tests of fixed 
effects were used to analyze the difference between a-syn and the control at each 
timepoint. A natural log transformation was performed to correct for violation to the 
assumption of constant variance between groups. * p < 0.05; Y-axis, logarithmic scale; 
N.S., not significant; OD, optical density.   
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of teal and mCherry; whereas unhealthy mitochondria are identified as having reduced or 
no co-localization. Moreover, in unhealthy mitochondria mCherry will diffuse throughout 
the cytoplasm. The lower the co-localization, the lower was the membrane potential. This 
is due to the inability of preCOX4-mCherry to enter the mitochondria when the 
membrane potential is lower, causing it to instead disperse throughout the cytoplasm. As 
shown in Figure 20, IntTox a-syn induced the formation of dense mitochondrial 
structures rather than as thread-like elongated structures under glycerol-ethanol. This may 
be due to large IntTox a-syn aggregates in glycerol-ethanol and thus, the mitochondrial 
structures are more closely packed together, compared to galactose condition. We also 
observed the disrupted membrane potential signal, i.e. the reduced overlap of teal and red 
both under galactose and glycerol-ethanol. Further mitochondrial structure specific 
examination is required to confirm the results of disrupted membrane potential signal. 
a-syn increases the percentage of cells that accumulate ROS under both conditions. 
We examined ROS production at 3, 6, and 18 h of induction in both conditions. ROS has 
been shown to increase a-syn aggregation while a-syn increases ROS production. Hence, 
we hypothesized that under both conditions, increased ROS production would be 
observed, however, more so under glycerol-ethanol condition since in glycerol-ethanol 
oxidative phosphorylation, the major source of ROS production, would be elevated in this 
condition. Further, since IntTox a-syn is more toxic in glycerol-ethanol; the toxicity may 
be mediated via increased ROS production. We first performed quantitative assessment 
of ROS using a plate reader. We observed that IntTox a-syn increased ROS levels at 6 h 
(p = 0.04) and 18 h (p < 0.001) in galactose and at 18 h (p = 0.002) in glycerol-ethanol 




Figure 20. Mitochondria show dense morphology under glycerol-ethanol and 
disrupted membrane potential signal under both galactose and glycerol-ethanol in 
the presence of α-synuclein. 
Single diploid yeast colonies containing both vector (pRS303-GAL) or IntTox a-syn 
(W303 MATa strain) and GAL3A368V (W303 MATα strain) were grown overnight in 
double selective 2% glucose media. The vector and α-syn strain were transformed with 
pMitoLoc which contains two (preSU9-CFP and preCOX4-mCherry) tags with 
mitochondrial targeting sequences. Teal represents all mitochondria and red represents 
healthy mitochondria. The culture was washed twice with distilled water and diluted to an 
OD600 of 1.0 and was grown in double selective 2% galactose and 3% glycerol with 1% 
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ethanol media, and induced for 18 h. At each time point, the cells were isolated and 3 µL 
of suspension was placed on a glass slide and aggregates were viewed under the YFP, 
CFP and Tx Red channels. SNCA encoding α-syn was tagged with YFP. CFP images 
were obtained by Z-stack. Images of mitochondria were merged using ImageJ. Scale bar: 





Figure 21. Quantitative assessment of reactive oxygen species under galactose and 
glycerol-ethanol conditions in the presence of α-synuclein.  
Single diploid yeast colonies containing both vector (pRS303-GAL) or IntTox a-syn 
(W303 MATa strain) and GAL3A368V (W303 MATα strain) were grown overnight in 
double selective 2% glucose media. The culture was washed twice with distilled water 
and diluted to an OD600 of 1.0 and was grown in double selective 2% galactose and 3% 
glycerol with 1% ethanol media, and induced for 3, 6 and 18 h. Cells were incubated with 
dihydroethidium (DHE) for 20 min in the dark and absorbance was measured at λex = 
485 nm and λem = 620 nm. The amount of ROS generated was calculated as the ratio of 
the absorbance to the OD600. Repeated measures ANOVA with a random subject effect 
were run to analyze the difference between a-syn and the control. The experiment was 
repeated three times and the bars represent mean + SE. * p < 0.05 and hence significantly 





























ROS under the two conditions. However, upon closer examination many cells were 
stained with red fluorescence (Figure 22 A) in both conditions. We then examined the 
proportion of these bright red cells (Figure 22 B) and determined that there were more in 
both conditions in the presence of IntTox a-syn (both p < 0.004) with no apparent 
difference between the two conditions. The bright red fluorescent cells appeared dead 
under bright field microscopy. Hence, the higher ROS that was seen with the plate reader 
measurement was likely due to the higher red fluorescence emitted by the large number 
of cells that accumulate ROS. Taken together these results suggest that no significant 
increase in ROS production occurred, however, increased cell death due to accumulation 
of ROS was observed in both conditions. 
Finally, we sought to examine if IntTox a-syn localizes to the mitochondrial 
matrix, thereby directly inhibiting its function under glycerol-ethanol. For this, we used a 
previously validated split GFP system, where the first ten GFP b-sheets (GFP1-10) are 
tagged with the mitochondrial targeting sequence and the 11th b-sheet (GFP11) is tagged 
with the gene of interest, in our case, SNCA. We did not see mitochondrial targeting of a-
syn in either condition (Figure 23). However, we used CIT1, a mitochondrial matrix 
protein, as a positive control, which also did not show targeting to the matrix. Assuming 
the intervening stop codon prevented the transcription of the gene, we performed PCR 
analysis and Yeast Gap Repair to remove it. We also confirmed the in-frame sequence of 
SNCA in the GFP11 construct. However, we were still unable to observe targeting with the 
positive control. Thus, although the construct required to perform the targeting 
experiment has been created, further experimental optimizations are required before the 
targeting of a-syn to mitochondrial matrix can be confirmed. Although we were unable 
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to directly detect mitochondrial targeting, we did observe dense mitochondrial structures 
under glycerol-ethanol and were, therefore, able to corroborate the findings of the 




Figure 22. Number of cells that accumulate ROS are elevated under galactose and 
glycerol-ethanol conditions in the presence of α-synuclein.  
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The same sample of cells from Figure 22 was used for microscopic imaging. Three 
microliters of cells were placed on the glass slide and viewed under YFP (α-syn) and Tx 
Red (ROS) channels. ROS, when generated in the cells react with DHE and emit red 
color; the intensity of the red color indicates the amount of ROS. (A) ROS and α-syn in 
galactose and glycerol-ethanol at 3, 6 and 18 h of induction. (B) Quantification of the 
cells that accumulate ROS (bright red fluorescence in [A]) in two conditions at 18 h of 
induction. Proportion of cells that accumulate ROS were calculated as the ratio of the 
number of bright red fluorescent cells to the total number of cells. The experiments were 
repeated three times and the bars represent mean + SE. Two-way ANOVA was used to 
analyze the difference between α-syn and the control. Data had to be natural log 
transformed in order to adhere to the assumption of constant variance * p < 0.05 and 
hence significantly different compared to control. Scale bar: 5 µm. BF, bright field; N.S., 






Figure 23. Targeting of a-synuclein to mitochondria was not successful.  
SNCA (W303 MATa strain) was tagged with GFP11; this strain was also transformed 
GFP1-10 with a mitochondrial targeting sequence tagged with mCherry. Single diploid 
yeast colonies containing both SNCA (GFP11 tagged) and GAL3A368V (W303 MATα strain) 
were grown overnight in double selective 2% glucose media. The culture was washed 
twice with distilled water and diluted to an OD600 of 1.0 and grown in double selective 
2% galactose and 3% glycerol with 1% ethanol media, and induced for 18 h. Cells were 
isolated and 3 µL of suspension was placed on a glass slide. Cells were viewed under 
GFP and Tx Red channels. Mitochondria appeared red (Tx Red channel) and a-syn, if 
targeted to mitochondria, should appear green (GFP channel) due to GFP fusion. Scale 









V. AIM 3: TO SCREEN AND CHARACTERIZE THE SUPPRESSORS OF INTTOX 
a-SYNUCLEIN TOXICITY UNDER GLYCEROL-ETHANOL  
 
Rationale 
Screening of overexpressed a-syn genes in yeast under galactose conditions has 
contributed to the elucidation of the pathophysiology, genetic interactions, and biological 
pathways underlying Parkinson’s disease.39,42,64,65,100,101 In our study, we observed 
previously unknown phenotypes of a-syn under glycerol-ethanol. However, genetic 
screening to identify modifiers of a-syn has not yet been performed under glycerol-
ethanol condition.  Previous genetic screening techniques require first identifying yeast 
genes that can modify toxicity, and only after identifying its human homolog can the 
effects of the modifier be further analyzed. Since our lab has a collection of 
approximately 15,000 human genes cloned into yeast expression vectors, we designed a 
model for a human gene library and GAL3A368V, effectively bypassing the need for cross-
species comparisons and allowing for the direct screening of human gene modifiers of 
IntTox a-syn toxicity under glycerol-ethanol. 
Experimental design 
Human gene library and genetic screening by mating. To study human genes in yeast, 
our laboratory has successfully cloned 14,827 full-length sequences verified to be human 
gene clones into the Gateway yeast expression vector pRS416-GAL1-ccdB. Each 
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overexpressed human gene clone was transformed into the WT haploid strain W303 
MATa containing a-syn. This yeast strain was mated with a strain containing GAL3A368V 
(W303 MATa). The diploid yeast was grown in selective media for 48 h before plating on 
glucose (negative control) and glycerol-ethanol plates (Figure 24). We did not perform 
screening in galactose condition as IntTox a-syn was not toxic under diploid galactose 
conditions. 
Confirmation of genetic hits. Scoring of the genetic hits was performed by visually 
examining the phenotypes of the yeast strain in glycerol-ethanol agar plates (Figure 25). 
Four types of scoring were employed: trace, mild, moderate, and strong. We chose 184 
hits and the original plasmid of these hits was revived from the bacterial glycerol stock. 
The process of plasmid isolation and individual transformation into yeast are described 
under Methods (Confirmation of genetic hits). Once the yeast strains were ready, the 
toxicity was re-evaluated by spotting of the diploid strains. This verification step allowed 
us to exclude false positives.  
Results 
3.1: To identify human gene suppressors of IntTox a-synuclein toxicity under 
glycerol-ethanol  
Unique suppressors of IntTox a-syn are identified under a glycerol-ethanol. Based on 
an initial screening of 14,827 human genes, we identified 184 hits that suppressed the 
toxicity of α-syn under glycerol-ethanol conditions. After confirmation, 87 hits remained. 
The confirmed suppressors were compared with the list of suppressors of IntTox a-syn 
toxicity under haploid galactose conditions (previously performed in our lab). Of these 87 




Figure 24. Schematic representation of the yeast overexpression screening to 
identify suppressors of IntTox a-synuclein toxicity under glycerol-ethanol.  
(A) Human gene clones (14,827) were cloned into a yeast expression vector and 
individually transformed into a yeast strain. The yeast strains were then stored as glycerol 
stocks in individual wells of 96-well plates. (B) The human genes were transformed into 
a strain containing a-syn, which were then mated with a strain of the opposite mating 
type containing the GAL3A368V allele. (C) The diploid yeast strain was selected and 




Figure 25. Sample image of spotting showing a suppressor of IntTox α-synuclein in 
glycerol-ethanol agar plate.  
IntTox a-syn and human gene clone were transformed into the W303 MATa strain. 
GAL3A368V was transformed into the W303 MATα strain. Single colonies from both 
strains were grown in 96-well plates. Each strain was transferred into a single 96-well 
plate containing YPD media and grown overnight for mating. The mixture was then 
transferred to another 96-well plate containing double selective 2% glucose media for 
selection of diploid strains containing a-syn, human gene clone and GAL3A368V. The 
culture was grown for 48 h and then spotted onto 2% glucose and 3% glycerol with 1% 
ethanol agar plates. The agar plates were incubated for 3–5 days, at which point the 
images were obtained. The background growth in glycerol-ethanol shows the toxic 
phenotype of a-syn. The yellow box highlights a suppressor. Each diploid strain was 




mitochondrial-related functions.  
Gene ontology analysis of the hits in suppressor screening of IntTox a-syn under 
glycerol-ethanol. We used 87 hits from the glycerol-ethanol screening to perform the GO 
term enrichment analysis and identified groups of genes that are enriched based on 
molecular function, biological process and cellular compartment (Table 4). Based on 
molecular function, the analysis showed a 14.2-fold enrichment in genes with RNA 
polymerase II distal enhancer sequence-specific DNA binding, followed by an 8.9-fold 
enrichment with DNA-binding transcription activator activity, RNA polymerase II-
specific, and 5.1-fold enrichment of RNA polymerase II regulatory region DNA binding. 
Based on biological process, the analysis showed a 22.1-fold enrichment of genes 
involved in embryonic skeletal system morphogenesis, 12.0-fold enrichment of 
anterior/posterior pattern specification and a 5.0-fold enrichment of positive regulation of 
transcription by RNA polymerase II. A cellular component-based analysis showed 2-fold 
enrichment of genes in the nucleoplasm while approximately 0.2-fold 
underrepresentation of genes in the integral component of the membrane and the 
organelle membrane was observed. 
14-3-3 protein isotypes suppress IntTox a-syn toxicity under glycerol-ethanol 
condition. Of the eight hits that had mitochondrial-related functions, four of them were 
14-3-3 isotypes (Table 5). There is a total of seven 14-3-3 protein isotypes, of which our 
library had six (b, q, g, z, s, and h). The one isotype we did not have was 14-3-3ε. Of the 
six isotypes, four (b, q, g, and z) suppressed the toxicity of IntTox a-syn (Table 5). We 
confirmed the end-read sequencing of all six 14-3-3 isotype clones.   
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819 28 5.63 4.98 + 5.95E-09 
Cellular Component 




3600 5 24.73 0.2 - 0.0003 
Organelle 
membrane 2469 3 16.96 0.18 - 0.02 
The enrichment analysis was performed using the online tool as described under 
Methods (Gene Ontology enrichment analysis). The analysis list included all genes 
that were confirmed as suppressors (n = 87) of toxicity in glycerol-ethanol plates in 
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the large-scale screening analysis. The reference list included the list of genes from 
the human library (n = 12,890). Duplicate clones were removed prior to analysis. A 
Fischer’s exact test was used and Bonferroni correction for multiple testing was 
selected. Only results with Bonferroni-corrected for p < 0.05 are displayed. The 
analysis was run based on molecular function (A) biological process (B) and cellular 
component (C). n represents the number of hits matching the criteria. Number (#) 
of hits represent the number of IntTox α-syn suppressors that map to this 
annotation data category. Fold enrichment (fifth column) is calculated by the online 
software based on the number of actual hits in comparison to the number of 
expected hits (fourth column). Over (+) or under (-) represented denotes if the 




Table 5. 14-3-3 protein isotypes that suppressed the IntTox a-synuclein toxicity 
under glycerol-ethanol condition. 
Gene 
name 
Protein name Significance102 
14-3-3β 14-3-3 protein β/α Present in tangles in Alzheimer’s 
disease 
14-3-3𝛉  14-3-3 protein theta Present in Lewy bodies in 
Parkinson’s disease 
14-3-3γ  14-3-3 protein gamma Present in Lewy bodies in 
Parkinson’s disease 
14-3-3𝜻 14-3-3 protein zeta/delta Present in Lewy bodies in 
Parkinson’s disease 
There is a total of seven 14-3-3 protein isotypes. Of the seven, six were included in 
our human gene library. Of the six, four 14-3-3 proteins suppressed the a-syn 




3.2: To characterize the 14-3-3 isotype suppressors of IntTox a-synuclein toxicity 
14-3-3 isotypes suppress the toxicity but do not reduce aggregate formation of IntTox 
a-syn under glycerol-ethanol. We used all six 14-3-3 isotypes (4 suppressors and two 
non-suppressors) to perform a spotting assay. Figure 26 shows that only four of the six 
isotypes (b, q, g, and z) can suppress the toxicity of IntTox a-syn toxicity under glycerol-
ethanol. Galactose was used as a control where no toxicity with IntTox a-syn was 
observed. As shown in Aim 2, IntTox a-syn shows toxicity in galactose in a haploid 
yeast strain. Hence, we performed spotting assays in the haploid condition without 
GAL3A368V. Interestingly, the 14-3-3 suppressor isotypes did not suppress the toxicity in 
galactose (Figure 27). Whether the suppressor isotypes instead enhance the toxicity of 
IntTox a-syn in galactose condition requires further investigation.  
Next, we quantified the proportion of cells containing a-syn aggregates in the 
presence of 14-3-3 isotypes (Figure 28 A and B). 14-3-3q, 14-3-3g, and 14-3-3z did not 
reduce the percentage of cells with aggregates; while 14-3-3b increased (p = 0.02) the 
proportion of cells with aggregates. Further, the non-suppressor isotypes, 14-3-3s, and 
14-3-3h did not increase the aggregates. We also observed that the protein expression 
level of a-syn was not affected by the 14-3-3 suppressor subtypes (Figure 29 A and B). 
14-3-3 isotypes do not increase the viability and respiratory competency of cells. We  
predicted that the suppressors may increase the amount of viable and respiratory-
competent cells. However, the 14-3-3 isotypes did not significantly impact the viability, 






Figure 26. Four 14-3-3 isotypes suppress the toxicity of IntTox a-synuclein in 
glycerol-ethanol.  
The W303 MATa strain containing IntTox a-syn was transformed with an empty vector 
(pRS416-GAL) or 14-3-3 isotypes. Single diploid yeast colonies containing both IntTox 
a-syn (with 14-3-3 isotypes) and GAL3A368V (W303 MATα strain) were grown overnight 
in double selective 2% glucose media. The culture was washed twice with distilled water 
and diluted to an OD600 of 1.0 and was spotted (left-most column). The diluted culture 
was further serially diluted 10-fold and spotted four times. The dilution was repeated 
until the last column on the right. The dilution is indicated by the tapering triangle bar on 
the top. Cells were then spotted onto solid double selective agar plates containing 2% 
glucose (negative control), 2% galactose (positive control), or 3% glycerol and 1% 






Figure 27. Four 14-3-3 isotypes do not suppress the toxicity of IntTox a-synuclein in 
galactose. 
The W303 MATa strain containing IntTox a-syn was transformed with an empty vector 
(pRS416-GAL) or 14-3-3 isotypes. Single haploid yeast colonies containing both IntTox 
a-syn (with 14-3-3 isotypes) were grown overnight in double selective 2% glucose 
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0 
and was spotted (left-most column). The diluted culture was further serially diluted 10-
fold and spotted four times; the dilution was repeated until the last column on the right. 
The dilution is indicated by the tapering triangle bar on the top. Cells were then spotted 
onto solid double selective agar plates containing 2% glucose (negative control), 2% 








Figure 28. 14-3-3β increases IntTox a-synuclein aggregates in glycerol-ethanol. 
IntTox a-syn was transformed with an empty vector (pRS416-GAL) or 14-3-3 isotypes. 
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. The culture was washed twice with distilled water and diluted to an OD600 of 1.0 
and was grown in double selective 3% glycerol with 1% ethanol media and induced for 
18 h. Cells were isolated and 3 µL of suspension was placed on a glass slide and 
aggregates were viewed under the YFP channel. Scale bar: 5 µm. BF, bright field (A). 
Quantification of the aggregates (B) was performed using ImageJ and verified by manual 
counting. The experiments were repeated three times and a minimum of 200 cells were 
counted for each isotype. Bars represent mean + SE. Dunnett’s test was performed to 
compare each 14-3-3 isotype to the vector. *p < 0.05 and hence significantly different 



















































Figure 29. 14-3-3 suppressor isotypes do not reduce IntTox a-synuclein protein 
expression in glycerol-ethanol. 
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. IntTox a-syn was transformed with an empty vector (pRS416-GAL) or 14-3-3 
isotypes. The culture was washed twice with distilled water and diluted to an OD600 of 
1.0 and was grown in double selective 3% glycerol with 1% ethanol media and induced 
for 18 h. Cell cultures at an OD600 of 1.0 (1 x 107 cells) were isolated and the protein was 
extracted. SNCA encoding IntTox a-syn was tagged with YFP and an antibody against 
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GFP was used. The loading control protein used was PGK1. (A) shows the blotting 
images and (B) shows quantification of the bands. Image quantification was performed 
using ImageJ. The experiment was repeated three times, and the bar graphs represent 
mean + SE. Protein expression in the presence of vector was used as the reference value. 
Dunnett’s test was performed to compare each 14-3-3 isotype to the vector. *p < 0.05 and 
hence significantly different compared to the vector. N.S., not significantly different 





Figure 30. 14-3-3 suppressor isotypes do not increase viability or respiratory 
competency in glycerol-ethanol.  
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. IntTox a-syn has been transformed with an empty vector (pRS416-GAL) or 14-3-
3 isotypes. The culture was washed twice with distilled water and diluted to an OD600 of 







































































































for 18 h. Cells at an OD600 of 1.0 were harvested and diluted; 100 µL each of 10-4 dilution 
and 10-5 dilution were plated on YPD and YPGE agar plates to determine the number of 
viable (A) and respiratory-competent cells (B), respectively. Agar plates were incubated 
for 2–3 days and single colonies were counted. Colony counts from the dilution that were 
nearest to 100 were chosen. The colony counts were multiplied by the respective dilution 
factor and used for statistical analysis. Dunnett’s test was performed to compare each 14-
3-3 isotype to the vector. N.S., not significantly different compared to the vector. Y-axis, 




14-3-3 isotypes do not modify the mitochondrial structure or the disrupted membrane 
potential signal. We next transformed the 14-3-3 plasmids into the yeast strains 
containing pMitoLoc and examined the mitochondrial structure and membrane potential. 
When we examined the mitochondria, we did not see a reduction in the dense 
mitochondrial structures (Figure 31). Moreover, the 14-3-3 subtypes did not modify the 
disrupted membrane potential. When we examined the IntTox a-syn aggregates, we 
noticed that there were fewer than in the previous experiments (Figure 27). Hence, we 
compared the proportion of aggregates between the two experiments and found that there 
was a 12–71 percent difference between the two experiments. The highest difference in 
the percentage of aggregates occurred with the empty vector (41% decrease) and 14-3-3β 
(71% decrease).  
14-3-3 isotypes do not decrease the ROS production and 14-3-3β decreases the 
percentage of cells that accumulate ROS. Upon examining mitochondrial ROS with a 
plate reader, the 14-3-3 suppressors did not significantly reduce ROS production (Figure 
32). Further, under microscopic examination, no visible increase or decrease in ROS was 
noted (Figure 33 A). All 14-3-3 suppressor isotypes had lower percentage of cells that 





Figure 31. 14-3-3 isotypes do not modify the mitochondrial structure or the 
disrupted membrane potential signal.  
The IntTox α-syn strain were transformed with pMitoLoc which has two (TFP and 
mCherry) tags with mitochondrial targeting sequence. Teal (TFP) represents all 
mitochondria; read (mCherry) represents only healthy mitochondria. Single diploid yeast 
colonies containing both IntTox a-syn (W303 MATa strain) and GAL3A368V (W303 MATα 
strain) were grown overnight in double selective 2% glucose media. IntTox a-syn has 
been transformed with an empty vector (pRS416-GAL) or 14-3-3 isotypes. The culture 
was washed twice with distilled water and diluted to an OD600 of 1.0 and grown in double 
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selective 3% glycerol with 1% ethanol media and induced for 18 h. Cells were isolated 
and 3 µL of suspensions were placed on a glass slide and viewed under the YFP, CFP 
and Tx Red channels. SNCA encoding α-syn wasa tagged with YFP. CFP images were 
obtained by Z-stack. Images of mitochondria were merged using ImageJ. Scale bar: 5 







Figure 32. 14-3-3 isotypes do not decrease ROS production. 
Single diploid yeast colonies containing both IntTox a-syn (W303 MATa strain) and 
GAL3A368V (W303 MATα strain) were grown overnight in double selective 2% glucose 
media. IntTox a-syn was transformed with an empty vector (pRS416-GAL) or 14-3-3 
isotypes. The culture was washed twice with distilled water and diluted to an OD600 of 
1.0 and grown in double selective 3% glycerol with 1% ethanol media and induced for 18 
h. Cells were incubated with DHE for 20 min in the dark and absorbance was measured 
at λex = 485 nm and λem = 620 nm. The amount of ROS generated was calculated as the 
ratio of the absorbance to the OD600. Dunnett’s test was performed to compare each 14-3-




















































Figure 33. 14-3-3β decreases the percentage of cells that accumulate ROS. 
The same sample of cells from Figure 32 was used for microscopic imaging. Three 
microliters of the cells were placed on the glass slide and viewed under the YFP (α-syn) 
and Tx Red (ROS) channels. ROS, when generated in the cells reacts with DHE and 
emits a red color; the intensity of the red color indicates the amount of ROS. (A) ROS 
and α-syn in glycerol-ethanol at 18 h of induction. (B) Quantification of the cells that 
accumulate ROS (bright red fluorescence in [A]). Percentage of cells that accumulate 
ROS was calculated as the ratio of the number of bright red fluorescent cells to the total 
number of cells. The experiments were repeated three times and the bars represent mean 
+ SE. Dunnett’s test was performed to compare each 14-3-3 isotype to the vector. *p < 
0.05 and hence significantly different compared to vector. N.S., not significantly different 


























































VI.  DISCUSSION 
In Aim 1, we chose three GAL3 alleles - GAL3F237Y, GAL3A368V and GAL3S509P 
and tested their ability to induce the GAL1 promoter under non-galactose conditions. We 
used β-galactosidase assay to test the level of promoter induction. We also corroborated 
the findings from the β-galactosidase assay using a yeast spotting assay. We found that 
all three GAL3 alleles induced the GAL1 promoter in glycerol-ethanol condition (Figure 
3), however, the combination of these alleles did not induce the promoter (Figure 4) as 
the combinations failed to enable transition to a ‘closed active’ Gal3p conformation 
(Figure 5). Based on α-syn as the model in the spotting assay, we chose to use GAL3A368V 
for further experiments. Yet, when GAL3A368V was assessed in other non-galactose 
conditions, including caloric restriction and nitrogen starvation conditions, we found that 
it did not induce the GAL1 promoter in the presence of glucose (Figure 6). This finding 
was verified by spotting assay using α-syn, FUS, TDP-43 and HTT103Q (Figure 7). 
However, when glucose content was reduced from 0.5% to 0.1% and when the glucose 
was replaced with raffinose, we saw rapid induction of the GAL1 promoter (Figure 8). 
Under calorie restriction (0.1% glucose), raffinose and nitrogen starvation (2% raffinose), 
IntTox and HiTox a-syn overexpression caused differential toxicity and aggregate 
formation. Specifically, IntTox a-syn showed toxicity, however, did not exhibit 
aggregate formation in raffinose conditions (Figure 9 and 10); while HiTox a-syn did 
not induce toxicity yet showed aggregate formation under calorie restriction (Figure 9 
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and 11). This is the first study showing the uncoupling of toxicity and aggregate 
formation of a-syn. Results from Aim 1, therefore, show that GAL3A368V can be used to 
study genes in any non-galactose condition lacking glucose.  
We chose three GAL3 alleles from a previous publication75 where a haploid 
condition was utilized and the WT GAL3 was deleted. To this end, we first examined the 
GAL3 alleles in a diploid condition and then in the presence of WT GAL3. Our lab had 
previously validated genetic screening in diploid conditions98 and thus performing a 
screening with deletion of WT GAL3 from about 15,000 yeast strains containing human 
genes seemed impractical. For the first time, we have shown that GAL3 alleles can be 
constitutively active and induce the GAL1 promoter in diploid conditions in the presence 
of two WT GAL3 (from the two haploid strains). Once we understood that GAL3A368V 
activity need not be restricted to glycerol-ethanol but rather to any non-galactose 
conditions, we extended our analysis to other conditions including, calorie restriction and 
nitrogen starvation. We also found that GAL3 alleles are unable to induce the GAL1 
promoter in the presence of low glucose concentrations (0.5%). This is likely attributable 
to the significant suppressive function of glucose on the GAL1 promoter.77 Glucose 
represses GAL1 expression by three primary mechanisms.76 Firstly, glucose acts on the 
upstream activating sequence and reduces Gal4p (transcriptional activator) while 
increasing Gal80p (repressor) expression. Secondly, Mig1p, a transcriptional repressor 
binds to the upstream repression sequence and represses GAL1 expression in the presence 
of glucose. Thirdly, glucose inhibits the transcription of GAL2 encoded galactose 
permease and reduces the level of functional inducer in the cell. Thus, GAL3A368V was 
unable to circumvent this multi-tactical repression mechanism by glucose. 
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Additionally, we found that the combination of GAL3 alleles did not significantly 
increase GAL1 promoter strength. Structural analysis of Gal3p showed that the mutations, 
in combination, prevented the transition to the ‘closed active’ conformation of Gal3p. 
F237 of Gal3p sits in a hydrophobic pocket that is comprised of F247, M403, L65, F414, 
F418, and I245. A closed conformation will force the F237 from the hydrophobic pocket 
to a more hydrophilic site. Similarly, substituting phenylalanine for tyrosine in F237Y 
(i.e. a hydroxyl group) has the same result, effectively drawing the peptide out. The 
position in which the F237 extends from the pocket is where S509 is located. 
Alternatively, substituting serine for proline (S509P) prevents F237Y from popping out 
of the hydrophobic pocket and, thus, the combination of alleles cancels the transition to a 
closed conformation.73 
Finally, the most interesting finding of this Aim was the discrepancy between 
toxicity and aggregate formation observed with IntTox and HiTox a-syn overexpression 
in non-galactose conditions. Previously, all studies involving a-syn report the presence of 
cellular toxicity or neurodegeneration with the presence of a-syn inclusions.103 However, 
here we are the first to comprehensively demonstrate that a-syn can augment or attenuate 
toxicity irrespective of the presence of inclusions, depending on the growth conditions. 
Although understanding this discrepancy requires further investigation, we hypothesize 
potential causes for these observations. Under caloric restriction conditions, the lifespan 
of yeast cells becomes extended and subsequently the decline of UPR is abrogated.104 In 
addition, calorie restriction maintains autophagy (the cell’s recycling machinery) in 
homeostasis by reducing Sir2 activity.94 Thus, it may be that under calorie restriction, the 
cell’s protective mechanisms (UPR and autophagy) neutralize the presence of aggregates 
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and reduce cellular toxicity. In case of raffinose condition, no aggregates were observed 
although toxicity was apparent with IntTox a-syn. This may have been caused by 
raffinose activating alternate signaling pathways that reduce ROS production and/or 
cytochrome c release.105 Further experiments testing the level of ROS and cytochrome c 
can help explain if these mechanisms are responsible for the absence of aggregates 
despite the presence of toxicity. Reduction of ROS and cytochrome c will result in 
reduction of mitochondrial stress. Reduced mitochondrial stress means functional 
mitochondria and we know that a-syn requires a functional mitochondria in yeast to 
produce toxicity.44 Thus, the protective signaling mechanisms activated under raffinose 
likely reduces the mitochondrial stress to a level that can prevent aggregate formation but 
not to a level that can suppress toxicity caused by IntTox a-syn overexpression.  
In Aim 2, we saw that IntTox α-syn was toxic under glycerol-ethanol but not 
under galactose in diploid yeast strains (Figure 13). Although we did not observe an 
increase in α-syn protein expression (Figure 16) in the glycerol-ethanol condition that 
would explain the higher toxicity, we did see an increase in the proportion of cells with α-
syn aggregates under glycerol-ethanol (Figure 17) compared to galactose conditions, that 
may provide a partial explanation for the observed toxicity. IntTox α-syn did not affect 
the respiratory competency in galactose but rather affected it only under glycerol-ethanol 
(Figure 19). We also observed dense mitochondrial structures predominantly under 
glycerol-ethanol condition (Figure 20). Based on quantitative and microscopic 
assessment, we concluded that increased ROS reading with IntTox α-syn overexpression 
is due to increased percentage of cells that accumulate high-level of ROS (Figure 21 and 
22). From Aim 2, it can be concluded that the increased toxicity of IntTox α-syn in 
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glycerol-ethanol condition compared to galactose is due to increased aggregate 
formation, decreased number of viable and respiratory-competent cells and the presence 
of dense mitochondrial structures. The other parameters including protein expression 
level, membrane potential, ROS production and presence of cells that accumulate ROS 
did not differ significantly between the two conditions and thus, cannot explain the 
increased toxicity in the glycerol-ethanol condition.  
Under glycerol-ethanol, we saw that the toxicity of all genes – SNCA (IntTox and 
HiTox), FUS, and TDP-43 – increased. a-syn affects the mitochondria in multiple ways 
and reduces the respiratory cellular activity. Hsp60, a mitochondrial chaperone, mediates 
FUS entry into the mitochondria and in transgenic flies, and thus, downregulation of 
Hsp60 rescues mitochondrial defects and neurodegenerative phenotypes caused by FUS 
overexpression.106 TDP-43 preferentially binds mitochondrial mRNAs of complex I 
subunits ND3 and ND6 eventually causing complex I disassembly.107 In a transgenic 
TDP-43 mutant mouse model, disrupting the mitochondrial localization of TDP-43 
results in abrogation of mitochondrial dysfunction and neuronal loss. Thus, it is possible 
that under glycerol-ethanol condition, there is an increase in toxicity of all genes that 
affect the mitochondria.  
We observed both toxicity and aggregates with IntTox a-syn in diploid glycerol-
ethanol and haploid galactose strains. Further, the level of toxicity between the two 
strains as determined via spotting and liquid growth assays, was similar. However, when 
we compare the percentage of aggregates between the two strains, we see fewer in 
haploid galactose conditions (37%) compared to glycerol-ethanol (56%). It is, therefore, 
important to note that these two conditions cannot be directly compared and are not 
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interchangeable with differing underlying mechanisms of toxicity associated with each. 
Further, we observed that when IntTox a-syn is induced in haploid and diploid 
conditions, toxicity is completely absent in diploid. A proteome quantification study 
using stable-isotope labeling of amino acids in haploid and diploid yeast cell cultures 
showed unaltered expression levels of approximately 4,500 proteins between haploid and 
diploid wild-type yeast.108 Only a few proteins involved in pheromone signaling and cell 
wall structure were upregulated in haploid yeast. We do not, however, understand 
whether these subtle changes in protein levels are sufficient to suppress the toxic 
phenotype of a-syn. A direct comparison of mitochondrial structure and mitochondria-
related functions including ROS production, cytochrome c release, apoptosis, and 
mitochondrial membrane potential between haploid and diploid condition in the presence 
of GAL3A368V and a-syn might help explain the differences in toxicity between the two 
strains. 
Under galactose condition, in contrast to what we hypothesized, we did not 
observe reduced respiratory competency with a-syn overexpression. This result, along 
with an absence in mitochondrial structure alterations in galactose conditions denotes that 
a-syn does not affect the mitochondrial function under galactose to the same extent as in 
glycerol-ethanol. If the mitochondria are not functioning at their full capacity, as in the 
case of galactose, a-syn does not seem to affect the mitochondrial function. 
Alternatively, in glycerol-ethanol, when cell survival is dependent on mitochondrial 
function, a-syn reduces mitochondrial function as well as respiratory competency. The 
N-terminal amphipathic domain of α-syn has been reported to be associated with 
alterations in mitochondrial morphology and the activation of mitochondrial permeability 
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transition pores.109 This was associated with a decrease in mitochondrial cardiolipin 
content. Glycerol-ethanol may induce changes in mitochondrial structures and thus 
becomes vulnerable to the action of a-syn.  
Despite previous reports showing higher ROS production by a-syn under 
galactose conditions,69,110 in our study, a-syn did not increase ROS production in the two 
conditions. These previous studies measured ROS using quantitative techniques and as 
such, the cells that accumulate ROS with red fluorescence may have been included in the 
measurements and overlooked. Had we not performed the microscopic examination, we 
too would have concluded that ROS production was indeed higher in the presence of a-
syn. Hence, plate reader measurements must be re-evaluated by excluding the 
fluorescence emitted by the cells that accumulate ROS. Also, the reason as to why ROS 
production was not increased by a-syn in our study remains unclear. The DHE dye that 
we used primarily identifies cellular and not mitochondrial superoxide.111 The by-
products of this reaction include a ethidium (nonspecific redox product) and 2-
hydroxyethidium (adduct of superoxide).112 The wavelengths of these two by-products 
overlap and thus, provide inconsistent results in a regular plate reader and in microscopic 
images. The use of high-pressure liquid chromatography may serve to circumvent this 
problem. Although we do not fully know which ROS species becomes induced by a-syn, 
hydrogen peroxide rather than superoxide appears to dominate.113 Techniques to identify 
different types of ROS would assist in better addressing these questions. 
We measured the number of cells that accumulate ROS and found that they 
increased in the presence of a-syn in both conditions although, there was no difference 
between the two conditions. To identify the specific apoptotic stage of cells, further 
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testing using Annexin V/propidium iodide (PI) co-staining is useful. This stain quantifies 
externalization of phosphatidylserine, an early apoptotic event, and membrane 
permeabilization, indicative for necrotic death. It also allows for the discrimination 
between early apoptotic (Annexin V positive, PI negative), late apoptotic (Annexin V 
positive, PI positive), and necrotic (Annexin V negative, PI positive) cells. Staining at 
different time points during growth in the two conditions and their correlation with the 
presence of aggregates can help predict the sequence of the two events.  
YCA1 is the yeast orthologue of mammalian caspase; the deletion of YCA1 
abolishes the ROS accumulation induced by a-syn, suggesting that caspase is the key 
mediator in ROS production. We can, therefore, determine if deletion of YCA1 prevents 
or reduces apoptosis in the glycerol-ethanol condition. Alternatively, pan-caspase 
inhibitor Q-VD-OPh114 can be used to examine the role of caspase in apoptotic cell death 
induced by a-syn in glycerol-ethanol. Nevertheless, the amount (< 25%) of apoptosis 
alone cannot explain the increased toxicity in the glycerol-ethanol condition. Hence, it 
can be concluded that mitochondrial function plays a dominant role in inducing apoptosis 
and toxicity in glycerol-ethanol. 
In Aim 3, using yeast mating technique validated in our lab,98 we screened 14,827 
human gene clones (corresponding to 12,890 genes) to identify suppressors of IntTox α-
syn in glycerol-ethanol. There were 184 hits in the screen, however, after performing a 
confirmation step, only 87 remained. When this list was compared with the hits obtained 
from the haploid galactose condition performed in our lab, we found that 43 of the 87 hits 
were present only under glycerol-ethanol. Further, GO enrichment analysis of IntTox α-
syn suppressor hits showed significant overexpression of genes related to the function of 
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RNA polymerase II (Table 4). Any process that activates or increases the frequency, rate 
or extent of transcription from an RNA polymerase II promoter were overrepresented in 
suppressors of IntTox α-syn. Genes associated with anterior-posterior pattern 
specification were also overrepresented. Anterior-posterior pattern specification is a 
process in which specific areas of cell differentiation are determined along the anterior-
posterior axis during neuronal development. Additionally, homeobox proteins dominated 
both RNA polymerase II and anterior-posterior pattern specification groups. Genes that 
belong to nucleoplasm were overrepresented whereas genes that belonged to organelle 
membrane were underrepresented among the confirmed suppressors.  
Interestingly, among the 43 hits, four of the 14-3-3 isotypes (b, q, g, and z) 
emerged as suppressors of IntTox α-syn only in glycerol-ethanol and not in galactose 
condition (Table 5 and Figure 26 and 27). Whether 14-3-3 isotypes enhanced the 
toxicity of IntTox α-syn in galactose must be confirmed in subsequent analyses. 
Nevertheless, 14-3-3β increased the number of IntTox α-syn aggregates (Figure 28) 
although this result was not consistent across other experiments. 14-3-3 suppressor 
isotypes neither reduced protein expression levels (Figure 29) of IntTox a-syn nor 
increased viability and respiratory competency in glycerol-ethanol (Figure 30). 
Moreover, no changes in mitochondria was observed (Figure 31), and ROS production 
was not decreased (Figure 32) by the 14-3-3 suppressors. However, 14-3-3β was found 
to decrease the proportion of cells that accumulate ROS (Figure 33). This Aim unraveled 
some unique patterns of suppressors – the involvement of RNA polymerase II, anterior-
posterior axis morphogenesis and nucleus. Although we were unable to characterize how 
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the four 14-3-3 proteins suppressed IntTox α-syn toxicity in glycerol-ethanol, we were 
able to rule out certain mechanisms. 
The overrepresentation of genes involved in RNA polymerase II function and 
anterior-posterior axis specification highlights the fact that modification at the 
transcriptional level and early neuronal development play key roles in suppressing the 
toxicity of IntTox α-syn in glycerol-ethanol. Further, these groups were dominated by 
homeobox proteins. Homeobox genes are a group of  approximately 250 genes each 
containing a 60-amino acid homeodomain that is responsible for DNA binding and 
regulation of hindbrain morphogenesis and axial skeleton patterning by acting as 
transcriptional regulators.115 Two of the homeobox protein suppressors, LHX4 and OTX1, 
have been shown to be present in dopaminergic neuron progenitor cells in the midbrain 
and to regulate their development.116,117 Homeobox proteins, EN-1 and EN-2, in addition 
to regulating transcription also regulate mRNA translation. Specifically, in two (mutant 
α-syn and MPTP toxin-induced) Parkinson’s disease model, EN-1 and EN-2 were shown 
to regulate Ndufs1 and Ndufs3 translation, two mitochondrial complex I proteins, and 
prevented dopaminergic neuron death in vivo.118 Thus, homeobox genes are dynamic in 
that they not only regulate gene transcription but are also able to regulate translation of 
mitochondrial proteins in dopaminergic neurons. Although it is unlikely that homeobox 
proteins regulate the expression of the GAL1 promoter driven SNCA in yeast, the protein 
levels of α-syn need to be examined to rule out this possibility. Alternatively, the 
suppressor genes could alter the expression of other yeast genes, alleviating the toxicity 
of α-syn.  
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Four isotypes of 14-3-3 protein was found to suppress the toxicity of IntTox α-syn 
in glycerol-ethanol. 14-3-3 proteins have 40% homology to α-syn, colocalize with a-syn 
and accumulate in Lewy bodies in Parkinson’s disease brains.119 14-3-3 proteins play key 
roles in neuronal cell division and differentiation through phosphorylation of mitogen-
activated protein kinase kinase by activating gene transcription.120 Specifically, 14-3-3h 
binds with aggregate prone oligomers of a-syn; while overexpression of a-syn sequesters 
and downregulates 14-3-3h.121 When 14-3-3g, 14-3-3q, and 14-3-3e were overexpressed 
in neuroglioma cells, a reduction in the number of aggregates was observed.122 We did 
not observe such a reduction in the number of aggregates with any of the 14-3-3 
suppressor isotypes. In fact, we saw an increase in the amount of aggregates with 14-3-
3b. We also saw a variation in the percentage of aggregates between experiments. We are 
unsure of the cause of such variations between experiments. It might be worth integrating 
one or more copies of the 14-3-3 genes in the yeast genome to re-examine their effect on 
α-syn aggregation.  
Next, 14-3-3 proteins exhibit anti-apoptotic functions by binding to, and 
sequestering, pro-apoptotic Bad.123,124 In our study, we saw that 14-3-3β reduced the 
proportion of cells that accumulate ROS. Hence, the suppression of toxicity may be 
partially explained by the anti-apoptotic effect of 14-3-3. This must be validated as yeast 
does not contain the mammalian anti-apoptotic machinery. Specifically, YCA1, an 
orthologue of caspase in yeast, can be deleted and the suppressive effect retested with 14-
3-3β. Alternatively, a pan-caspase inhibitor, Q-VD-OPh,114 can be used to test the role of 
apoptotic inhibition in the suppressive function of 14-3-3β. 
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Finally, we did not see any changes in mitochondrial structure, membrane 
potential, ROS production, viability or respiratory competency with 14-3-3 suppressor 
proteins; thus, an alternate explanation for the suppressive effect must exist and may rely 
on that information. As mentioned before, 14-3-3h, 14-3-3g, 14-3-3q, and 14-3-3e have 
been shown, in in vitro and other models, to sequester a-syn and reduce the formation of 
aggregates.120,121 It is interesting to see similar findings of a-syn toxicity suppression in a 
simple eukaryotic cell, yeast. Although we do not know the exact mechanisms underlying 
the suppressor effect of 14-3-3 isotypes in yeast, we speculate that a direct interaction 
between the 14-3-3 isotypes and a-syn could be involved. The binary interaction can be 
tested using yeast-two-hybrid assay. Alternatively, other conserved functions of 14-3-3 in 
yeast might be at play. Such functions might be affected by carbon source, since the 
suppressor effect was not observed on galactose. It would be interesting to determine if 
14-3-3 was able to suppress the toxicity on raffinose condition to better understand if the 
a-syn aggregation foci are involved. Finally, the proposed mechanisms need to 










Three GAL3 alleles - GAL3F237Y, GAL3A368V and GAL3S509P - induced GAL1 promoter in 
glycerol-ethanol condition, however, the combination of the alleles did not induce the 
promoter. GAL3A368V did not induce GAL1 promoter in the presence of glucose. IntTox a-
syn induced toxicity in raffinose without aggregate formation. HiTox a-syn failed to 
induce toxicity yet formed aggregates under caloric restriction. IntTox α-syn was toxic 
under glycerol-ethanol yet not under galactose. IntTox α-syn protein levels were not 
increased but the aggregates were increased in glycerol-ethanol compared to galactose. 
Respiratory competency was reduced, while cell population that accumulated ROS was 
increased by IntTox α-syn in glycerol-ethanol. By screening 14,827 human gene clones, 
we identified 87 hits as suppressors of IntTox α-syn toxicity. GO enrichment analysis of 
the suppressor hits showed significant overexpression of genes related to the function of 
RNA polymerase II, anterior/posterior pattern specification and nucleoplasm. These three 
categories were enriched with genes of the homeobox proteins pointing toward 
transcriptional regulation playing a vital role in suppressing toxicity of IntTox α-syn in 
glycerol-ethanol. Four of the 14-3-3 isotypes (b, q, g, and z) emerged as the suppressors 
of IntTox α-syn only under glycerol-ethanol. 14-3-3β increased the number of aggregates 
of IntTox α-syn. 14-3-3 suppressor isotypes neither reduced protein expression levels of 
IntTox a-syn nor increased viability and respiratory competency in glycerol-ethanol. 
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Mitochondrial structure was unchanged, and ROS production was not decreased by the 
14-3-3 suppressors. 14-3-3β decreased the percentage of cells that accumulated ROS. 
Our study obliterates the limitation of performing screening only under galactose 
condition. Future studies should focus on pinpointing the difference in transcription and 
translation between galactose and glycerol-ethanol conditions since the parameters tested 
did not provide a clear answer. Although yeast is a single eukaryotic cell with no 
neurons, it still possesses the conserved cellular biology that underpins Parkinson’s 
disease pathology. Therapeutic targets identified in prior α-syn yeast screening analyses 
have been validated in higher organisms highlighting the relevance of this system in 
studying Parkinson’s disease. Although there are aspects of this disease which are beyond 
the scope of yeast, with the advancement of system and computational biology, large-
scale yeast genetic data on a-syn and Parkinson’s disease can be efficiently analyzed and 
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